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ABSTRACT 
This study assessed healthcare providers’ knowledge, attitudes and practices 
towards IPT provision for people living with HIV (PLHIV) in Addis Ababa, the 
capital city of Ethiopia.  
A quantitative, descriptive, cross-sectional study design was used for the study 
and data was collected using a self-administered questionnaire from 104 
clinicians working in ART clinics. 
The findings show that healthcare providers who participated in this study had a 
mean value of high knowledge, positive attitude and good practice towards IPT 
provision for PLHIV.  Significant association was found between knowledge and 
attitude (P=0.000) but no significant associations were found between 
knowledge and practice, attitude and practice as well as between the type of 
facility (public/private) and level of practice.   
This implied that, the low level of IPT implementation in Addis Ababa doesn’t 
seem due to health care providers’ lack of knowledge and resistance to provide 
IPT for people living with HIV. As a result, the researcher recommends for 
further researches of other possible factors like; the reliability of IPT 
information/data management, drug supply and the leadership and governance 
of the health system that IPT program is a direct concern. 
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CHAPTER 1 
ORIENTATION TO THE STUDY 
 
1.1  INTRODUCTION 
The Human Immunodeficiency Virus (HIV) pandemic presents a massive 
challenge to the control of tuberculosis (TB). In high HIV prevalence populations, 
TB is a leading cause of morbidity and mortality, and HIV is fuelling the TB 
epidemic. HIV increases susceptibility to infection with mycobacterium 
tuberculosis, the risk of progression to TB disease, and the incidence and 
prevalence of TB. It also increases the likelihood of re-infections and relapses of 
TB. It has also been found that latent TB-infection in HIV-positive persons 
reactivates at a rate of 5 to 15% per year as compared to 5 to 10% over a 
lifetime for HIV-negative persons. HIV-positive persons are prone to re-infection 
with new strains of TB from the community and drug resistance may occur more 
frequently (Ethiopian Federal Ministry of Health (EFMoH) 2008:3).  
According to the World Health Organization (WHO) factsheet on TB/HIV, almost 
one in five deaths of among people living with HIV (PLHIV) is due to TB. In 
2010, of the 1.8 million HIV-related deaths, 350,000 were due to TB (WHO 
2011a). In the same year, WHO estimated 8.8 million incident cases of TB 
globally, of which 2.3 million were HIV positive. Among the total HIV positive TB 
patients globally, 82% live in sub-Saharan Africa (WHO 2011b:61). 
TB/HIV co-infection is profound in resource-limited countries with high TB 
prevalence and HIV infection rates. Africa is facing the worst TB/HIV burden in 
the world. In 2010, of the 2.3 million TB/HIV incident cases, 900,000 (39%) were 
living in the African region (WHO 2011b:70). 
In response to the dual epidemics of HIV and TB, WHO has recommended 12 
collaborative TB/HIV activities as part of core HIV and TB prevention, care and 
treatment services. These include interventions that reduce the morbidity and 
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mortality from TB in people living with HIV (PLHIV), such as the provision of 
antiretroviral therapy (ART) and the three I’s for HIV/TB: intensified case-finding 
of TB (ICF), isoniazid preventive therapy (IPT) and infection control for TB 
(WHO 2011c:8). IPT was first recommended by WHO and Joint United Nations 
Program on HIV/AIDS (UNAIDS) in 1998 (WHO 1998:225). 
Isoniazid is given to individuals with latent infection with Mycobacterium 
tuberculosis in order to prevent progression to active disease. Exclusion of 
active TB is critically important before IPT is started. The absence of all of 
current cough, night sweats, fever, or weight loss can identify a subset of 
adolescents and adults living with HIV who have a very low probability of having 
TB disease that can reliably be initiated on IPT. This screening rule has a 
negative predictive value of 97.7% (95% CI [confidence interval] 97.4–98.0) at 
5% TB prevalence among people living with HIV (Getahun, Granich, Kittikraisak 
& Varma 2011). In children, the absence of poor weight gain, fever and current 
cough can identify children who are unlikely to have TB. Isoniazid is given daily 
as self-administered therapy for at least 6 months as part of a comprehensive 
package of HIV care for all eligible people living with HIV irrespective of degree 
of immunosuppression, ART use, previous TB treatment and pregnancy. 
Information about IPT should be made available to all people living with HIV 
(WHO 2011c:10-16). 
IPT is efficacious and is recommended for all people living with HIV in countries 
where tuberculosis is common and in all those with documented co-infection, 
regardless of where they live (WHO 1998:211). But yet, this global 
recommendation has not been widely implemented in the world. In 2010,only 
12% of the reported number of people living with HIV newly enrolled in HIV care 
was put on IPT worldwide. Intensified efforts are needed to approach the global 
targets of providing screening for TB for all those enrolled in HIV care and 
providing IPT to all those attending HIV care services who are eligible for IPT by 
2015 (WHO 2011b:66). 
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Ethiopia is one of the highly affected countries by the TB/HIV co-epidemic and 
one of among the 22 high burden countries (HBC) in Tuberculosis. According to 
the WHO TB incidence estimation, Ethiopia ranked 9th in the world and 3rd in 
Africa in 2010. The incidence and prevalence of TB burden for the same year 
was estimated at 261 and 394 per 100,000 populations, respectively (WHO 
2011b:54).On the same fact, the national HIV/AIDS factsheet indicates that 
about 1,216,908 Ethiopians were living with HIV/AIDS and 28,073 individuals 
have died as a result of infection with the virus in 2010. The national HIV 
prevalence rate in adults (15-49 years) was 2.4%, with marked variation 
between urban (7.7%) and rural populations (0.9%)(Ethiopia Federal Ministry of 
Health HIV/AIDS prevention and control office (EFMOH-HAPCO) 2010). 
Recognizing the high prevalence of TB and HIV in the country and following the 
WHO’s interim policy recommendations on IPT in 2004, the EFMoH launched a 
policy to implement the collaborative activities between TB and HIV/AIDS 
programs since 2005 (EFMoH 2008:17). The major objectives of the 
collaborative activities were to decrease the burden of TB among PLHIV and 
vice versa to decrease the burden of HIV among TB patients through regular 
screening of HIV patients for TB in HIV clinics and providing HIV counselling and 
testing services for TB patients in TB clinics. PLHIV who is found to be free from 
active TB after the standard screening for TB symptoms will be given Isoniazid 
for prevention treatment. Some of the major advantages of IPT are: prevention 
of progression of latent TB into active TB, improve quality of life, decrease 
mortality in children and prevention of further transmission of TB in the 
community, at large (EFMoH 2008:17). 
To support this collaborative effort, Ethiopia adopted the international IPT 
guideline and developed the first national TB/HIV implementation guideline in 
2005; where IPT is one of the key component in the guideline. Consecutively, 
TB/HIV working group was established at national and regional levels to 
accelerate the implementation of collaborative TB/HIV activities through effective 
collaboration between National TB and AIDS Control programs and other 
stakeholders (EFMoH 2008: iv).  
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1.2. BACKGROUND INFORMATION TO THE RESEARCH PROBLEM 
 
1.2.1 The source of the research problem 
Despite the fact that Ethiopia exerts effort to widely scale up the implementation 
of IPT, reports reveal a very low performance at the national level.  According to 
the EFMoH TB control program report, the trend of IPT utilization rate among 
eligible PLHIV is decreasing since it started in 2006 and was consistently less 
than 30% for the last three years. As shown in Figure 1.1 below, only 21% of 
PLHIV who were negative from TB were put on IPT in 2009/10 (EFMoH 
2011:22).  
 
Source: FMoH of Ethiopia annual TB bulletin, March 2011. Issue No 4 
Figure 1.1 Proportion of eligible HIV positive clients put on IPT: 2006/07-2009/10-FMoH 
The study conducted in Addis Ababa also showed that the proportion of PLHIV 
provided with IPT was as low as32.0% and the proportion of having information 
about IPT among study participants was 29.8% (Wesen & Mitike 2012).  
In 2010, the Stop TB Department of WHO assessed the implementation of IPT 
for PLHIV worldwide and reviewed the critical health system barriers for its 
nationwide implementation. The results revealed that, barriers to the 
implementation of IPT were diverse and can occur from global to facility levels.  
The fear of development of drug-resistant TB among program managers and 
service providers was commonly cited as one of the reason for limited scaling up 
(Getahun, Granich, Sculier, Gunneberg, Blanc, Nunn & Raviglione 2010). 
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A study conducted in Thailand on physicians’ adherence to the IPT guideline 
showed that only 19% of the surveyed physicians provided IPT for PLHIV 
(Hiransuthikul, Hiransuthikul, Nelson, Jirawisit, Paewplot & Kasak 2005).   
Another study in South Africa also powerfully suggested that doctors’ resistance 
to prescribe IPT for their TB-negative HIV patients has a contribution on TB 
epidemic. The study states that there has been significant anecdotal evidence 
about clinician resistance across the country to use the WHO-recommended 
preventive TB therapy and the study concluded that a change in health care 
worker perception is needed if IPT was to be widely used in the public sector 
(Bateman 2011).  
1.2.2 Research problem 
EFMoH (2011:22) persistently reported an under achievement of IPT 
implementation in the country. For the last three years (2007/8 - 2009/10), less 
than 30% of PLHIV who were free from TB were put on IPT; this is far beyond 
the target set by the Global Stop TB plan which is to achieve 100% of eligible 
people living with HIV to be put on IPT by 2015.  
The problem of low IPT implementation in Ethiopia has been recognized since 
before and various studies conducted in the related areas. However, all previous 
studies were focused on patients' perception and adherence rate but no study 
was conducted on the perspective of healthcare providers towards their 
perception and practice on IPT provision for PLHIV. 
In contrast, various studies conducted worldwide identified that healthcare 
provides' perception and non-compliance with the WHO IPT recommendations 
were cited as the common barriers for the wide use of IPT in many countries. It 
has also been reflected that the reason for barriers were because of lack of 
knowledge, experience and clarity on the benefits of IPT by the health care 
workers (Getahunet al 2010). In addition, Bateman (2011) explains that 
perceived operational barriers included a number of practical issues that 
clinicians were prohibitive to the use of IPT; one was that using isoniazid without 
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other TB medications would induce drug resistance.  Another perception barrier 
was the belief that exclusion of active TB would be difficult in settings with a high 
prevalence of TB and HIV infection.  
1.2.3 Statement of the research problem 
EFMoH has in place the national TB/HIV implementation guideline since 2005 to 
guide healthcare providers on effective delivery of TB/HIV collaborative 
activities, including IPT. Nevertheless, the proportion of IPT utilization among 
PLHIV remained low (< 30%) in Ethiopia since 2007/8(EFMoH2011:22). 
Despite the low implementation of IPT in Ethiopia, there seem to be no previous 
studies conducted to know how healthcare providers perceive and practice IPT 
according to the national guideline and WHO recommendations.  
1.3 AIM OF THE STUDY 
The aim of this study is to widely scale up IPT implementation in Addis Ababa 
and in the country, as appropriate by identifying the level of knowledge, attitude 
and practice of healthcare providers towards IPT provision and determining if 
significant associations exist between IPT practice and their level of knowledge 
and attitude. 
1.3.1 Research purpose 
The purpose of the study is to assess healthcare providers’ knowledge, attitude 
and practice towards IPT provision for people living with HIV in Addis Ababa, 
Ethiopia. 
1.3.2 Research objectives 
The specific objectives of this research were to: 
 Assess the level of healthcare providers’ knowledge regarding IPT 
implementation and its treatment management. 
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 Assess healthcare providers’ attitude towards IPT efficacy or its benefit 
for PLHIV. 
 Assess level of healthcare providers’ practice towards IPT provision for 
eligible PLHIV.  
 Determine if relationship exist between healthcare providers' IPT practice 
and their level of knowledge and attitude. 
 Determine if a relationship exists between healthcare providers' IPT 
practice and their working settings (private vs public health facilities). 
1.4 SIGNIFICANCE OF THE STUDY 
The finding of this research is anticipated to promote effective implementation of 
IPT in Ethiopia by further improving the knowledge, attitude and practice of 
healthcare providers’ towards IPT provision for their eligible HIV patients. The 
study will benefit for the people living with HIV to get access of INH as 
appropriate as possible and prevent them from the risk of active TB 
development. It will also contribute for researchers by identifying the areas of 
gap for further researches.  
1.5 DEFINITIONS OF KEY CONCEPTS 
The key terms used in this study were defined and explained as applied 
throughout the dissertation so that the readers can share the intended meaning 
with the researcher. 
Attitude: 
Attitude is a state of mind involving beliefs, feelings, values and dispositions to 
act in certain ways (Medical dictionary. [s.a.]). 
In this study attitude refers to the perception or feeling of healthcare providers 
on the benefit/effectiveness of IPT and any preconceived ideas they may have 
towards it.  
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Clinician: A health professional, such as a physician, psychiatrist, psychologist, 
or nurse, involved in clinical practice, as distinguished from one specializing in 
research (Medical dictionary. [s.a.]). In this study clinicians include: physicians, 
health officers and nurses. 
Healthcare provider: is an individual or an institution that provides preventive, 
curative, promotional, or rehabilitative health care services in a systematic way 
to individuals, families or communities (Wikipedia. [s.a.]). 
Isoniazid:  also known as isonicotinylhydrazine (INH) is an organic compound 
that is the first-line medication in prevention and treatment of TB (Bateman 
2011). 
Isoniazid Preventive Therapy (IPT):   is the provision of the drug isoniazid to 
people at high risk of developing active tuberculosis (TB) (Bateman 2011). 
Knowledge;  
Knowledge is defined as ‘facts, information, and skills acquired through 
experience or education; the theoretical or practical understanding of a subject’ 
(Oxford dictionary. [s.a.]). 
In this study ‘knowledge’ refers how healthcare providers are informed or 
understood regarding the benefit of IPT and its risk management. 
Practice: 
Practice is defined as ‘the actual application or use of an idea, belief, or method, 
as opposed to theories relating to it’ (Oxford dictionary [Sa]). 
In this study practice refers to the prescription or provision of IPT by healthcare 
providers for people living with HIV based on the set WHO recommendations.  
1.6 CONCEPTUAL FRAMEWORK 
A framework is the structure of the idea or concept and how it is put together. It 
guides the researcher during the development of the study and enables the 
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researcher to link the findings to the body of knowledge (Burns & Grove 
2005:37). 
Based on the IPT guidelines and literatures reviewed, the researcher developed 
a conceptual framework for this study shown below (Figure 1.2). The structure 
depicts that the practice behaviour of healthcare providers towards IPT provision 
could be directly or indirectly affected by the socio-demographic characteristics 
(such as, age, sex, professional level, experience, training), knowledge of IPT 
(such as; screening for IPT eligibility, identifying eligible groups, managing INH 
preventive drug dose and its side effects) and the attitude they have towards IPT 
efficacy as well as the confidence on the screening tools to exclude active  
TB among PLHIV. As tried to show using the arrows, associations may exist 
between the practice behaviour of healthcare providers towards IPT provision 
and their socio-demographic characteristics, level of knowledge and attitude.  
  
10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Conceptual framework of the study 
 
1.7   RESEARCH SETTING 
The study was facility-based at 22 ART clinics in Addis Ababa, the capital city of 
Ethiopia. Addis Ababa is the largest city and geographically located at the heart 
of the country (Figure 1.3). According to the population and housing census in 
2007, Addis Ababa has an estimated population of 2.74 million (1.43 male and 
1.31 female) and it is divided in to ten sub-cities of administrative units (Central 
Statistical Agency (CSA) of Ethiopia 2008: 8) 
Attitude towards: 
 Effectiveness of IPT  
 TB screening tools 
 TB diagnosis capability in advanced HIV+ patients  
 TB diagnosis capability in HIV+ children  
 TB diagnosis capability in HIV+ pregnant woman 
Practice/ IPT Implementation: 
 Encouraging the patient for IPT use   
 Provide IPT for eligible HIV patients 
 Advising the patient for adherence 
 Manage for INH side effects 
 
Socio-demography 
 Sex, Age, Marital Status 
 Professional level 
 Clinical experience 
 Work settings: Public/private 
 Training 
 
Knowledge on: 
 Eligibility for IPT 
 Efficiency of IPT 
 Drug dosage 
 Side effects of IPT 
and its management 
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(Source: Clickable [n.d.]: [1]) 
Figure 1.3 Regional map of Ethiopia 
According to the health bureau of the city administration, there were a total of 68 
health facilities providing ART services in Addis Ababa as of June 2012. Of 
these, 47 were public, six non-government organizations (NGO) and 15 private 
health facilities. Table 1.1 shows the number of ART site distribution by sub-city 
and type of facility in Addis Ababa. 
Table 1.1 Distribution of facilities providing ART services in Addis Ababa. 
 
Type of Facility Total 
Sub-city Public * Public health NGO health Private 
Existing 
ART sites 
 
hospitals centres centres hospitals 
 
Addis Ketema 1 2 0 3 6 
Akaki-Kality 0 3 0 1 4 
Arada 2 3 1 1 7 
Bole 0 4 1 5 10 
Gulele 2 6 0 0 8 
Kirkose 2 3 0 2 7 
Kolfe-Keranio 1 4 1 2 8 
Lideta 1 6 0 0 7 
Nifas-Silk Lafto 0 3 0 0 3 
Yeka 1 3 3 1 8 
Total 10 37 6 15 68 
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1.8 RESEARCH DESIGN AND METHOD 
1.8.1  Design 
A quantitative, descriptive cross-sectional design was used to assess the level 
of healthcare providers’ knowledge, attitude and practice (KAP)towards IPT 
provision as well as to identify the possible relationships between practice 
behaviour and the level of knowledge and attitude. 
1.8.2  Methods 
1.8.2.1 Population 
As defined by Burns & Grove (2005:342), a population is the total set of study 
individuals or elements; in this case all healthcare providers who were working 
in ART clinics and providing clinical care and treatment services for people living 
with HIV were the population of this study. On estimation, around 413 total 
healthcare providers were expected working in Addis Ababa ART clinics (on 
average, seven clinicians in each 47 public and four clinicians in each 21 NGO 
and private ART clinics).  
1.8.2.2 Sample and sampling techniques 
A stratified cluster random sampling technique was employed to interview a total 
of 140 healthcare providers from the selected twenty-two ART service providing 
health facilities in Addis Ababa.  
1.8.2.3 Data collection instrument  
A structured and self-administered questionnaire was used to collect the 
required data for this study (see annexure A). The questionnaire was comprised 
of four sections;  
 Section-I: socio-demographic characteristics, 
 Section-II: Knowledge on IPT 
 Section-III: Attitude towards IPT efficiency and, 
 Section-IV: Practice of IPT provision for PLHIV. 
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1.8.2.4 Data analysis 
Data was entered using Epi-Info (windows version 3.5.4) which is a public 
domain statistical software developed by Centres for Disease Control and 
Prevention (CDC), Atlanta, USA. The data was then exported to a statistical 
package for social scientists (SPSS V21.0) for descriptive statistical analysis 
and association test between the study variables, as appropriate. 
1.9 ETHICAL CONSIDERATIONS 
All principles of ethical consideration were maintained throughout the study. 
Rights to participants 
Ethical consideration in this study was ensured through respecting the right of 
each respondent to self-determine for participation in the study, keeping 
respondents’ information anonymous and confidential – accessible only by the 
researcher. Since the study used only a self-administered instrument, no risk 
was associated during the data collection process and no harm was generated 
throughout the research process. 
Integrity  
Records on data collection were kept under lock for safety. No unauthorised 
person had access the information. All sources of information were 
acknowledged.  
Institutional rights 
Ethical approval was obtained from both, the Higher Degrees Committee of the 
Department of Health Studies at the University of South Africa (UNISA) 
(annexure B) and Addis Ababa City Administration Health Bureau (annexure D) 
before data collection commenced.  
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1.10 SCOPE AND LIMITATIONS OF THE STUDY 
The study was conducted in the selected health facilities of Addis Ababa that 
would be problematic to generalize the findings of the study to all clinicians who 
work outside the study sites in Addis Ababa and in Ethiopia, in general. Since 
the data collection instrument was self-reported, responses might be biased of 
respondents' feeling at the time they filled out the questionnaire. 
1.11 STRUCTURE OF THE DISSERTATION 
For ease of reading, this research report is structured as follows: 
Chapter 1: Orientation to the study 
Chapter 2: Literature review 
Chapter 3: Research design and method 
Chapter 4: Analysis, presentation and discussion of research findings 
Chapter 5: Conclusions and recommendations 
1.12 CONCLUSION 
This chapter briefly highlighted the background of the research, the research 
problem, research objectives and its significance for the population. The 
researcher also used this chapter to describe the design and method of the 
research that was used to collect the data and address the validity of the study.  
The researcher believed that this research is of most importance in identifying 
levels of knowledge, attitude and practice of healthcare providers towards the 
provision of IPT for PLHIV in the study area.  
Chapter 2 contains the literature review on which this study is based. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1  INTRODUCTION  
The previous chapter gave an introduction to the overall research contents; 
description to the research problem, purpose of the research, the research 
design and methods, significance of the research and the ethical considerations 
during the study. This chapter reviews literatures that are relevant to the 
implementation of IPT and its barriers focusing on the healthcare providers’ 
perspective worldwide and particularly in Ethiopia. A literature study provides a 
review of what others have done on the topic under this study.  
Burns & Grove (2005:37) explain that reviewing of literature is necessary 
because it provides insights on how others have investigated similar research 
problems. It orients the researcher to what has already been done about the 
topic. It helps the researcher to obtain adequate knowledge on the topic of 
interest, to know what has already been done about the topic and to understand 
the key information on the methods used by previous researchers. 
Therefore, several sources were consulted before the conduct of this study, 
including research books, medical and research journals, policy documents and 
guidelines. Documents related to the topic were reviewed such as; TB, HIV, 
TB/HIV collaborative activities and specifically, on the situation of isoniazid 
preventive therapy implementation in country and globally. The summary of all 
the literatures reviewed is shown in this section as follows. 
2.2 OVERVIEW OF TUBERCULOSIS AND HIV/AIDS 
An infectious disease is a disease that arises from the infestation of pathogenic 
microbial agents such as bacteria of humans or animals. For much of human 
history these diseases were the major causes of deaths worldwide. Even though 
communicable diseases have been on the fall in the major economies, the 
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contagious maladies such as tuberculosis and HIV/AIDS remain the most 
prevalent killers in the developing world. Especially, their co-infection forms the 
most deadly combination that negatively impacts not just the health but also the 
social, economical, political and security fabrics of the developing nations 
(Schlipköter & Flahault 2010). 
2.2.1 Tuberculosis 
TB is caused by Mycobacterium tuberculosis, a wide spread bacterial pathogen 
capable of prolonged survival within individuals in a state of latency or inactivity. 
This leads to an important distinction between latent TB infection, a state in 
which people are well, with normal medical investigations except for positive 
skin test reaction to injected TB purified protein derivative (PPD test) and TB 
disease. Individuals with TB disease usually have symptoms such as cough and 
weight loss as well as chest X-ray abnormalities and TB bacilli detectable at the 
site of tissue damage and disease (Churchyard & Corbett 2001). 
TB is transmitted by airborne droplets from person to person, and infection can 
be acquired only from individuals with active pulmonary TB. The risk of 
developing active TB is increased in latent infected individuals compared to that 
of infected free individuals. Latent TB bacilli are metabolically inactive and 
relatively insensitive to anti-TB drugs, so that treatment of infection, as distinct 
from disease, requires prolonged therapy to avoid a high risk of developing 
active TB (Jeong & Lee 2008). 
Under normal circumstances, the majority (90%) of those infected with TB will 
never become ill. Approximately, 10% of persons with normal immune systems 
who are infected with M. tuberculosis will develop TB disease at some point in 
their life. Conditions that are known to increase the risk of progression from TB 
infection to TB disease include; environmental factors including smoking, alcohol 
abuse, injection drug use, malnutrition and diet, socio-economic factors 
including overcrowding,  poor ventilation, hunger and poor nutrition, and medical 
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conditions including, diabetes mellitus, malignancies, measles, cortico-steroid 
therapy, immunosuppressive treatment and HIV infection (CDC. [s.a.]).  
According to Ringold, Lynn & Glass (2008:464), TB infection typically occurs 
after repeated or prolonged exposure to the coughing of an actively infected 
person. Individuals with HIV infection are at particularly high risk for contracting 
TB due to a lowered resistance to disease-causing organisms. TB can affect any 
organ in the body, but the lungs are the most common sites of infection. 
2.2.2 HIV/AIDS 
HIV infects cells in the immune system and the central nervous system. One of 
the main type of cells that HIV infects is the T helper lymphocyte. These cells 
play a crucial role in the immune system, by coordinating the actions of other 
immune system cells. A large reduction in the number of T helper cells seriously 
weakens the immune system. HIV infects the T helper cell because it has the 
protein CD4 on its surface, which HIV uses to attach itself to the cell before 
gaining entry. This is why the T helper cell is sometimes referred to as a CD4+ 
lymphocyte. Once it has found its way into a cell, HIV produces new copies of 
itself, which can then go on to infect other cells.  
Over time, HIV infection leads to a severe reduction in the number of T helper 
cells available to help fight disease. The number of T helper cells is measured 
by having a CD4 test and is referred to as the CD4 count. It can take several 
years before the CD4 count declines to the point that an individual needs to 
begin antiretroviral treatment. Without treatment, the CD4 count continues to 
decline to very low levels, at which point the individual is said to have 
progressed to AIDS.  
HIV infection can generally be broken down into four distinct stages: primary 
infection, clinically asymptomatic stage, symptomatic HIV infection, and 
progression from HIV to AIDS.  
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STAGE 1: Primary HIV infection  
During this stage there is a large amount of HIV in the peripheral blood and the 
immune system begins to respond to the virus by producing HIV antibodies and 
cytotoxic lymphocytes. This process is known as sero-conversion. If an HIV 
antibody test is done before sero-conversion is complete then it may not be 
positive.  
STAGE 2: Clinically asymptomatic stage  
This stage lasts for an average of ten years and, as its name suggests, is free 
from major symptoms, although there may be swollen glands. The level of HIV 
in the peripheral blood drops to very low levels but people remain infectious and 
HIV antibodies are detectable in the blood, so antibody tests will show a positive 
result.  
STAGE 3: Symptomatic HIV infection  
Over time the immune system becomes severely damaged by HIV and 
antiretroviral treatment is usually started once an individual’s CD4 count (the 
number of T helper cells) drops to a low level, an indication that the immune 
system is deteriorating. Treatment can stop HIV from damaging the immune 
system; therefore, HIV-infected individuals on treatment usually remain clinically 
asymptomatic. However, in HIV-infected individuals not receiving treatment or 
on treatment that is not working, the immune system fails and symptoms 
develop. Initially many of the symptoms are mild, but as the immune system 
deteriorates the symptoms worsen.  
Symptomatic HIV infection is mainly caused by the emergence of certain 
opportunistic infections (most commonly TB) that the immune system would 
normally prevent. This stage of HIV infection is often characterised by multi-
system disease and infections can occur in almost all body systems.  
STAGE 4: Progression from HIV to AIDS  
As the immune system becomes more and more damaged the individual may 
develop increasingly severe opportunistic infections and cancers, leading 
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eventually to an AIDS diagnosis.  A clinical criteria is used by WHO to diagnose 
the progression to AIDS, this differs slightly between adults and children under 
five, and depending on the guidelines of individual countries (WHO 2007b:8). 
2.3 BURDEN OF TUBERCOSIS AND HIV/AIDS 
As Martinson, Hoffmann & Chaisson (2011:290) state, the synergy between TB 
and HIV/AIDS is well established and is strong. It is found that in high HIV 
prevalence populations, TB is a leading cause of morbidity and mortality and 
HIV is attributed to fuel the TB epidemic.  
HIV infections is also noted to increase TB transmission rate at the community 
level  thereby increasing the risk of HIV-negative people contacting the disease 
and viciously contributing to the incidence and prevalence of TB in a given 
nation. The risk of developing TB is estimated to be between 20- 37 times 
greater in people living with HIV than among those without HIV infection (WHO 
2011c:8). 
2.3.1  Global burden of Tuberculosis 
Lönnroth & Raviglione (2008:481) state that about one third of the world’s 
population, or about 2 billion is estimated to be infected with the tuberculin bacilli 
and hence at risk of developing and transmitting the active disease anytime, 
especially so when the immune system gets compromised by other pathologic 
agents.  According to the WHO (2011b:11) report, there were an estimated 8.8 
million incident cases of TB (range, 8.5 million–9.2 million), equivalent to 128 
cases per 100 000 population globally in 2010.  Not surprisingly, over 85% of the 
incidences are reported to occur in the developing world with Asia taking 59% of 
the cases and Africa’s 26%; smaller proportions of cases were also reported in 
the eastern Mediterranean region (7%), the Europe (5%) and the Americas 
(3%). Overall, 81% of the global TB cases were estimated to occur in the 22 
HBCs that have been given highest priority at the global level since 2000. Of the 
22 HBCs, nine countries were in the African continent namely; South Africa, 
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Nigeria, Ethiopia, Kenya, Mozambique, the Democratic Republic of the Congo, 
Uganda, the United Republic of Tanzania and Zimbabwe (WHO 2011b:10).  
2.3.2 TB/HIV co-epidemic  
HIV is reported to accelerate the likelihood of re-infections and relapses of TB. 
Studies indicate that latent TB-infection in HIV-positive persons tend to 
reactivate at a faster rate of 5 to 15% per year as compared to 5 to 10% over a 
lifetime for HIV-negative persons. HIV-positive persons are prone to re-infection 
with new strains of TB from the community and drug resistance may occur more 
frequently (Sculier, Getahun & Lienhardt 2011:5). 
According to the WHO (2011a) factsheet, TB continues to be a serious health 
risk and is a leading cause of morbidity and mortality among people living with 
HIV. Of the 1.8 million HIV-related deaths in 2010, 350,000 were due to TB.  On 
the other hand, among the newly 8.8 million incident cases of TB globally in 
2010, 1.1 million (13%) were among people living with HIV and 82% of those 
HIV positive TB patients live in sub-Saharan Africa (WHO 2011b:61). 
The correlation between the dual TB and HIV infestation and poverty is 
pronounced in sub-Saharan Africa, especially in southern and east Africa. In 
2010, of the 2.3 million TB/HIV incident cases, 900,000 (39%) were living in the 
African region (WHO 2011b:70).  
2.3.3 National burden of TB and HIV/AIDS 
In Ethiopia, TB is the leading cause of death among PLHIV and the second in 
the general population (EFMoH 2009/10:32); Gele, Bjune & Abebe 2009:5). The 
country has seen a TB case increase of 2.6% annually, making it the most 
heavily afflicted country in the horn of Africa (WHO 2007a:19).  In 2010, the 
incidence and prevalence of all forms of TB in the country was estimated at 261 
and 394 per 100,000 populations respectively, that makes Ethiopia to rank 9th 
among the list of 22 HBCs in the world and 3rd in Africa. Furthermore, mortality 
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due to TB (excluding deaths among HIV-positive TB cases) in the same year 
was estimated to be 35 per 100,000 populations (WHOb 2011:12).  
The problem in the country is even more pronounced due to the existence of an 
already high HIV infection. According to EFMOH-HAPCO (2010) annual report, 
HIV prevalence rate in adults (15-49 years) was 2.4% in 2010, with marked 
variation between urban (7.7%) and rural populations (0.9%) that a total of 1, 
216,908 people were living with HIV and 28,073 died due to HIV. In the same 
year, the proportion of TB patients infected with HIV was 15% (EFMoH 
2011:22). From the study carried out in the Oromia regional state, the result 
showed that prevalence of HIV infection was significantly associated with the 
incidence of TB (r= 0.69, p<0.01) across the region (Bekele, Fleming, Habitamu 
and Fogarty 2009:65). These findings corroborate that TB, its co-morbidity with 
HIV/AIDS in particular, remain a disabling combination that warrant especial 
attention on the diagnosis, treatment and overall management in the country. In 
fact, several hospital-based cross sectional studies have reported that most of 
tuberculosis patients were co-infected with HIV, with recent estimates ranging 
from 46% to 65% (Kassu, Mengistu, Ayele, Diro, Mekonnen & Ketema 
2007:118). 
2.4 RESPONSE TO TB-HIV/AIDS DUAL EPIDEMIC 
Control of TB in HIV infected individuals represent a multi-factorial challenge 
both for the individual and for the nation in question. Since prevention is better 
than treatment, TB prophylactic therapy has been strongly recommended for 
people living with HIV/AIDS. 
2.4.1 Global response to the TB/HIV dual epidemic 
The wide presence of latent mycobacterium tuberculin in the global populace 
and the immune suppression ability of HIV create a perfect opportunity for the 
rapid development of active TB disease in HIV infected individuals. Hence to 
reduce the burden of TB in HIV infected individuals, WHO recommended TB 
preventive therapy back in 1998 along with other key intervention strategies 
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(WHO 2011c:11). Subsequently, in 2004 WHO issued a policy on TB/HIV 
collaborative activities to accelerate implementation of the twelve recommended 
guidelines. One such recommendation was that the significance of IPT to reduce 
the impact of TB/HIV co-infection (WHO 2004). Further, WHO (2011c: 11) has 
revised its policy on IPT in 2010 reiterating the importance of IPT as a core 
function of services provided to PLHIV and as a primary responsibility of 
National AIDS Programs. Since then a number of scientific studies have come 
up in supporting the beneficial effect of IPT both in the control of TB and 
improving in the quality of life for people living with HIV/AIDS.  Although there is 
a global consensus on the policy of TB/HIV, many countries have been slow to 
adopt the IPT recommendations and its nationwide implementation. WHO global 
TB control report indicates that  of the reported number of people living with HIV  
in 2010, only 12% have started IPT; much less than the global target of 
providing IPT to all those eligible PLHIV attending HIV care services by 2015  
(WHO 2011b:66).  
2.4.2 National response to TB/HIV dual epidemic 
Ethiopia has begun responding to the dual epidemics since 2001.  After an 
expressed commitment of the FMoH of Ethiopia to WHO’s call, the TB/HIV 
Advisory Committee (THAC) has been established in 2002 with key involvement 
of international and government stakeholders. The main objective of THAC is to 
coordinate and provide technical supports for the implementation of TB/HIV 
collaborative activities at national and sub-national levels. In 2004, the national 
TB/HIV collaborative activities strategy has been developed and started 
implementation in nine pilot sites of four regions in the country. In 2005, national 
implementation guideline for TB/HIV collaborative activities developed and the 
collaborative services have been scaled up including IPT (EFMoH 2008:5). 
Though IPT implementation has been started since 2005, the rate of its uptake 
among newly enrolled HIV patients showed a decreasing trend (see Figure 1.1).  
In 2010, according to the EFMoH (2011:22) TB/HIV routine surveillance data, 
only 21% of PLHIV were put on IPT in the country and 19% in Addis Ababa city 
administration. 
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2.5 ISONIAZID PREVENTIVE THERAPY (IPT) 
Isoniazid preventive therapy (IPT) is the use of isoniazid to sterilize latent 
infection with Mycobacterium tuberculosis and thus prevent progression to 
active disease. Prophylaxis with isoniazid (INH) has been shown to reduce the 
incidence of TB in HIV infected persons either by eradicating latent infection or 
preventing progression of new infection to active TB (WHO 2011c:26). Not only 
does HIV increases the risk of developing active TB in PLHIV it also increases 
the likelihood of re-infections and relapses of TB. In a population where HIV/TB 
is common, health services struggle to cope with the large and rising number of 
TB. In response to this challenge, WHO recommends the provision IPT to 
PLHIV after active TB is excluded.  Some of the major advantages of Isoniazid 
Preventive Therapy (IPT) are: 
 Prevention of progression of latent TB into active TB. 
 Help improve the quality of life. 
 Decrease mortality of children and 
 Prevention of further transmission of TB in the community, at large 
(EFMoH 2008:17). 
2.5.1   Efficacy of isoniazid preventive therapy (IPT) 
The efficacy of IPT in the prevention of a first episode of TB among persons with 
HIV infection or AIDS has been well demonstrated in various studies. A meta-
analysis from the Cochrane controlled trials register shows that provision of IPT 
to persons with HIV infection or AIDS in the absence of ART reduced TB 
incidence by 33% overall and by 64% among individuals with positive tuberculin 
skin test results, compared with placebo (Woldehanna & Volmink 2004).  An 
observational study also suggests that IPT reduces the risks of TB and death 
among PLHIV during early ART. Moreover, IPT and ART in combination result in 
a greater reduction in TB risk than does either treatment alone (Golub, Pronyk, 
Mohapi, Thsabangu, Moshabela, Struthers, Gray, McIntyre, Chaisson & 
Martinson 2009).  
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Despite such evidences, implementation of IPT in HIV care and treatment 
programs in resource-constrained environments has been limited for several 
years. One reason for this includes concerns about emergence of isoniazid 
resistance because of difficulty to exclude active TB; however findings from a 
systematic review suggesting that the effect of IPT on isoniazid resistance is 
likely to be small (Balclls, Thomas, Godfrey-Faussett & Grant 2006). Other 
concerns raised include the limited durability of isoniazid’s protective benefit and 
the need to provide adherence support to achieve high rates of adherence and 
treatment completion (Churchyard, Scano, Grant & Chaisson 2007) 
The guidelines group of WHO reviewed evidences from various studies on the 
provision of IPT and drug-resistant TB. The result of the meta-analysis 
concluded that INH resistance is not significantly associated with the provision of 
IPT. The relative risk of developing INH-resistant TB among all of those 
receiving isoniazid and found no statistically significant increased risk of 
resistance was (RR 95% CI= 1.87 [0.65–5.38]) (WHO 2011b:11). 
 In addition, the result from a case series study conducted in South Africa 
showed no risk of development of drug resistance after provision of IPT to gold 
miners with HIV/AIDS. The study concluded that “concerns about generating 
drug resistance should not impede implementation of isoniazid preventive 
therapy” (Halsema, Fielding, Chihota, Russell, Lewis, Churchyard & Grant 
2010).  
A systematic review of 12 randomized controlled trials with a total of 8,578 
participants from the Cochrane database also found out that preventive therapy 
versus placebo was associated with a lower incidence of active TB (RR 0.68, 
95% CI 0.54 to 0.85) (Akolo, Adetifa, Shepperd & Volmink 2010). 
Another study conducted on children in South Africa found out that prophylaxis 
with isoniazid has an early survival benefit and reduces incidence of tuberculosis 
in children with HIV (Heather, Mark, Stanzi, Janine, Gregory, Simon, Helena & 
Carl 2007:136). 
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Evidence from a clinical trial in Botswana also proved that HIV-infected patients 
who received isoniazid preventive therapy as part of a clinical trial had low rates 
of incident tuberculosis (Mosimaneotsile, Mathoma, Chengeta, Nyirenda, 
Agizew, Tedla, Motsamai, Kilmarx, Wells & Samandari2010).  
2.5.2. Healthcare providers' barrier to provide IPT for PLHIV 
Despite the strong evidence that isoniazid preventive therapy (IPT) reduces 
incidence of tuberculosis among people living with HIV, implementation of IPT 
remains low worldwide including Ethiopia.  
As stated in 2.5.1 above, healthcare providers usually resist prescribing IPT for 
their TB-negative HIV patients for fear of developing drug-resistant TB. 
According to the study in Thailand, physicians’ non-adherence to IPT guideline 
is found to be one of the limitations to the wide use of IPT. Among the 300 
participants of the study, who provided medical care for HIV-infected patients, 
only 19.3% of them provided IPT (Narin, Pornthip, Kenrad, Mayuri, Rawadi & 
Supawan 2005). 
A qualitative study was also conducted in South Africa to describe barriers to 
IPT implementation from healthcare providers and patients perspectives. From 
the study, it has been found out that primary barrier to IPT use was lack of 
knowledge and experience by health care workers. The health care workers 
were not aware of the benefits of IPT and unclear about guidelines. No patients 
had heard of IPT (Lester, Hamilton, Charalambous, Dwadwa, Chandler, 
Churchyard & Grant 2010:46).  
In 2010, Stop TB and HIV/AIDS departments of WHO assessed the progress in 
the implementation of isoniazid preventive therapy for people living with HIV 
worldwide. The study used a combination of systematic review of WHO data 
collection, document analysis and global expert opinions. The study concluded 
that barriers to the implementation of IPT are diverse and can occur from global 
to facility levels. Among the barriers, lack of experience, knowledge, and clarity 
on the benefits of IPT and existing guidelines by health care workers were cited 
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as important barriers for IPT provision rather than patient-related factors 
(Getahun et al 2010).  
Studies in Ethiopia also showed similar findings. The result from a cross- 
sectional study under taken in Addis Ababa hospitals showed that non-
adherence was observed among respondents who were not provided with 
sufficient information about IPT (Mesele, Amare, Fasil & Sibhatu 2011). Another 
facility-based cross-sectional survey was conducted to assess the status of IPT 
provision and awareness among PLHIV in Addis Ababa. The results were 
presented as the proportion of PLHIV ever had been provided with IPT were 74 
of 231 TB free PLHIV (32.0%) and the proportion of having information about 
IPT among study participants was 29.8% (Wesen & Mitike 2012). A prospective 
cohort study was also carried out in Hawassa, southern region of Ethiopia, to 
determine compliance to IPT and its effectiveness in children who have contact 
with TB patients. The study concluded that compliance to IPT in children is poor 
and this was associated with the parents’ perception of the low importance of 
chemoprophylaxis and healthcare providers were not providing adequate 
information while they put the patient on treatment (Kefyalew, Mohammed & 
Luis 2011).  
2.6 CONCLUSION  
This chapter has reviewed some of the literatures that were available regarding 
the burden of Tuberculosis and HIV/AIDS, the co-epidemic nature of TB and 
HIV, the effectiveness of isoniazid preventive therapy, and its implementation 
status worldwide and in Ethiopia. From the review, isoniazid preventive therapy 
has been shown to be safe and can significantly reduce the risk of active 
tuberculosis and death in HIV-infected persons.  However it has been also 
presented that IPT is under-utilized and the implementation status is low 
throughout the world including Ethiopia. Various reasons are mentioned 
contributing for low utilization of IPT where healthcare providers’ perception that 
IPT develops drug resistance is the one hindering its wider uses. 
Chapter 3 describes the research design and method that was used in this 
study. 
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CHAPTER 3 
RESEARCH DESIGN AND METHOD 
 
3.1  INTRODUCTION 
The previous chapter discussed literature review regarding the TB/HIV co-
epidemics and the use of isoniazid preventive therapy to reduce TB infection 
among HIV positive patients. It further described about IPT recommendations 
and when clinicians are expected to consider IPT for PLHIV. This chapter 
describes the approach which was used to assess the knowledge, attitude and 
practice of healthcare providers towards IPT provision for people living with HIV 
in Addis Ababa. It therefore includes description of the research design, 
population and sampling methods, research instrument, validity and reliability, 
data collection, data analysis, ethical considerations and finally the conclusion 
about the chapter.  
3.2  RESEARCH DESIGN 
Research design is the “architecture” of the study or the structured approach to 
be followed by the researcher to answer the questions raised by the research 
objective (Joubert & Katzenllenbogen 2007:77).  Burns & Grove (2011:253) also 
state that a research design is a blueprint for conducting a study that maximizes 
control over factors that could interfere with the validity of the findings. It is a 
plan guide for providing sound answers to a research questions. 
 A quantitative, descriptive cross sectional research design was used in this 
study; the choice of research design depends on the problem and purpose of 
the study and on the researcher's desire to generalize the findings (Brink, Walt & 
Rensburg 2006:53).  
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3.2.1  Quantitative research 
As described by Burns & Grove (2011:20), "quantitative research is a formal, 
objective, systematic process in which numerical data are used to obtain 
information about the world”. This study used quantitative research because 
numerical values are collected from respondents to assess systematically the 
level of knowledge, attitude and practice of healthcare providers towards IPT 
provision. This design was also chosen because of its ability to control the study 
through imposing conditions on the research situation so that biases are 
minimized and precision and validity are maximized (Polit & Beck 2004:15).  
3.2.2  Descriptive design  
Descriptive study is designed to gain more information about characteristics 
within a particular field of study (Burns & Grove 2011:256). Its purpose is to 
provide a picture of situations as it naturally happens. Polit & Beck (2008:192) 
concur, stating that the purpose of descriptive research design is to observe, 
describe and document aspects of a situation as it naturally occurs and 
sometimes to serve as a starting point for hypothesis generation or theory 
development. In this case, the researcher described the information as gathered 
from the healthcare providers' response regarding their perception and practice 
towards IPT provision for PLHIV and findings were documented as to be used 
for IPT scale up interventions and for further research idea. 
3.2.3  Cross-sectional study 
 A study design in which the data is collected at one particular point in time is 
called a cross-sectional research design (Polit & Beck 2008: 751). Cross 
sectional research design was used in this study because data were collected 
only once from the sampled group within a brief span of time. As stated in 
Bowling (2002:197), cross-sectional study is also less costly in terms of time and 
resource as a large sample can be studied within a relatively short period of 
time. 
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3.3  RESEARCH METHOD 
Research method is a way by which researchers use to structure their study in 
order to achieve their objectives (Polit & Beck 2008: 15). The following sections 
describe and discuss each of the following components of the research method 
employed in this study: the population, sample and sample size, method of data 
collection and data analysis. 
3.3.1  Sampling 
Sampling is the process of selecting a portion of the population to represent the 
entire population (Joubert & Katzenllenbogen 2007:94). According to Burns 
&Grove (2011:290), key concepts of sampling theory include populations, target 
population, sampling or eligibility criteria, accessible population, 
representativeness, sampling frames, and sampling plans or methods.  Each of 
these components are discussed below. 
3.3.1.1 Population 
Population is a particular group of individuals or elements who are the focus of 
the research. The target population is the entire set of individuals or elements 
who meet the sampling criteria. An accessible population is the portion of the 
target population to which the researcher has reasonable access (Burns &Grove 
2011:290). In this study, the population comprised all healthcare providers who 
were involved in clinical practice in Addis Ababa health institutions and the 
target population was healthcare providers who are clinicians and met the 
following inclusion criteria. 
Inclusion criteria: 
 Clinicians in ART clinics who deliver care and treatment services for 
people living with HIV and, 
 Had previous experience in ART/HIV clinics for at least six months. 
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Joubert & Katzenllenbogen (2007:95) describe that a sampling frame is a list of 
or some representation of the study population, either individuals or groups of 
individuals. As it was difficult to find list of healthcare providers by name, the 
sampling frame in this study comprised the list of ART clinics in Addis Ababa. 
Sample frame of the ART clinics were further stratified by the type of health 
facilities they are belonging; public and private sectors so that respondents of 
healthcare providers from both public and private sectors were adequately 
represented in the study. Stratification ensures that all levels of the identified 
variables are adequately represented in the sample (Burns & Grove 2011:301).  
3.3.1.2  Sample and sampling 
Polit & Beck (2008: 765) define a sample as a subset of a population selected to 
participate in a study and sampling is the process of selecting a portion of the 
population to represent the entire population.  
Sampling involves selecting a group of people, events, behaviours, or other 
elements with which to conduct a study. Researchers select study subjects from 
the sampling frame which is the list of every member of the population using a 
sampling plan or methods (Burns & Grove 2011:290).    
3.3.1.2.1 Sampling procedures  
The sampling method is designed to increase representativeness and decrease 
systematic variation or bias (Burns & Grove 2011:298).   The researcher used 
stratified cluster random sampling method to select the total number of 
healthcare providers, the study participants. 
Based on Burns & Grove (2011:302), "in cluster sampling, a researcher can 
develop a sampling frame that includes a list of all the states, cities, institutions, 
or organization with which elements of the identified population can be linked", 
in this case the health institutions or ART clinics was taken as a sampling frame. 
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Stratified random sampling is used in situations in which the researcher knows 
that some of the variables in the population are critical for achieving 
representativeness (Burns & Grove 2011:301). To ensure that both the public 
and private sectors of health institutions are represented in the sample, the 
sample frame was first stratified in to public and private stratum then sample 
ART clinics were selected randomly from each stratum in which all eligible 
clinicians in the selected ART clinics were participants of this study.   
3.3.1.2.2 Sample size 
Sample size is the number of respondents who are necessary for the 
achievement of a statistically valid conclusion (Polit& Beck 2008: 348). This 
requirement dictates the minimum number of participants who have to be 
included in the sample (Polit & Beck 2008: 413). The sample size was 
calculated using the minimum sample size determination for population 
proportion (Joubert & Katzenllenbogen 2007:347) as: 
   n =     P (1-P) * (Z2) 
D2 
Where: 
n= Sample size,  
P =  Expected frequency value that healthcare providers had good knowledge, 
attitude and practice towards IPT provision was taken as 50%, since the 
prevalence was not known. 
Z =  the reliability coefficient; Z=1.96 at 95% CI and  
D=  relative precision or the precision required on either side of the proportion 
 is taken as 10% (d = 0.1). 
Calculating the formula above, it returns n= 96.  
To correct for the difference in design effect due to cluster sampling, the sample 
size is again multiplied by the design effect (D=1.2). Therefore, n x D = 96 x 1.2 
= 115 
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And considering 10% contingency for recording error or non-responses, the total 
sample size that the researcher considered to be necessary in order to obtain 
statistically significant results was, n= 126. 
From the experience, on average, seven and four clinicians work in a single 
ART clinic of public and private health facilities, respectively. Therefore, 
considering the number of existing functional ART clinics and the probability 
proportional to size (PPS) technique, a total of twenty-two ART clinics; sixteen 
from the public and six from the private health facilities were selected randomly 
that 96 and 30 clinicians were contacted during data collection in the selected 
public and private ART clinics, respectively. 
 3.3.2  Data collection  
Burns & Grove (2005:430) describe data collection as "the process of selecting 
subjects and gathering data from these subjects".  
3.3.2.1  Data collection instrument  
A self-administered structured questionnaire (annexure A) was developed 
specifically for this study in order to collect the data from respondents. As stated 
in Burns & Grove (2005: 398), "questionnaires can be designed to determine 
facts about the subject or persons known by the subject; facts about events or 
situations known by the subject; or beliefs, attitudes, opinions, levels of 
knowledge or intentions of the subject". 
The data collection instrument or the questionnaire was prepared in consulting 
with TB/HIV program managers, literatures reviewed and referring the recent 
guidelines on IPT implementation and intensified TB case-finding in resource-
constrained settings (WHO 2011c:10-26).  The instrument comprised the 
following sections: 
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Section I: Socio-demographic data 
There were eight questions in this part. The questions include sex, age, marital 
status, religion, professional level, clinical experience in HIV clinics and whether 
trainings on TB/HIV as well as IPT were provided or not. 
Section II: Knowledge on IPT provision and its management  
There were ten questions in this part and were asked to know the knowledge of 
healthcare providers on IPT eligibility criteria, IPT provision and its management. 
Nine of the questions were multiple choices while one was an open ended 
question that allows respondents to express their ideas on the implementation 
situation of IPT in their working area. A correct answer for each close ended 
questions was given 1 score and 0 score for a wrong answer. The score varied 
from 0 - 9 points and was classified into 3 levels according to the Blooms' (1956) 
cut off point, 60-80% as follows: 
High level (80-100%)  7 - 9 scores 
Moderate level (60-79%)  5 - 6 scores 
Low level (less than 60%)  0 - 4 scores 
Section III: Attitude towards IPT provision for PLHIV  
This part includes the attitude of healthcare providers towards IPT provision for 
people living with HIV in the aspect of its efficiency and side effects. There were 
a total of ten questions; one open ended question and nine positive statements 
with Likert scale options of choice ranging from strongly agree to strongly 
disagree. The rating scale was measured as follows: 
Strongly agree  5 
Agree 4 
Undecided 3 
Disagree 2 
Strongly disagree 1 
34 
 
The scores varied from 9 to 45 and all individual answers were summed up for 
total and calculated for means. The scores were classified in to 3 levels (Positive 
Attitude, Neutral Attitude and Negative Attitude). 
Positive Attitude  36 - 45 scores (80%-100%) 
Neutral Attitude  27 - 35 scores (60%- 79%) 
Negative Attitude  09 - 26 scores (Less than 60%) 
Section IV: Practice towards IPT provision for PLHIV  
Ten questions have been included in this part. The eight questions ask about 
how often the healthcare providers provide IPT for PLHIV and monitor the 
treatment as per the national guideline, while two questions were open ended 
asked about major interventions required for the successful implementation of 
IPT in their working areas.  Most of the eight closed ended questions had three 
choices and those that were responded to have more than three answers were 
re-coded into three frequencies of IPT practice. The rating scale of responses 
was measured as follows: 
Yes, always   2 
Yes, sometimes  1 
No    0 
Hence the scores in measuring the practice of healthcare providers towards IPT 
provision and its treatment management was varied from 0 to 16, and were 
classified into 3 levels according to the Bloom's cut off point, 60-80% (Bloom 
1956). The levels of practice were: 
 Good  (80-100%)    12 - 16 scores  
 Fair  (60-79%)    9 - 11 scores  
 Poor  (Less than 60%)   0 - 8 scores  
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3.3.2.2  Pre-testing data collection instrument  
Burns & Grove, (2007:549) defines a pilot study as a smaller version of a 
proposed study conducted to develop and refine the methodology, such as the 
treatments, instruments, or data collection process to be used in the later study. 
The data collection instrument was pre-tested on five experienced clinicians (two 
physicians and three nurses) at Zewditu Memorial hospital ART clinic which 
were not included in the actual study. The shortcomings identified during the 
pre-testing such as; ambiguity, relevance and consistency of the questions were 
corrected and additional points; like IPT recommendation period for HIV patients 
with previous history of TB, was included. 
3.3.2.3  Data collection procedure  
Burns & Grove, (2007:536) define data collection as “identification of subjects 
and the precise, systematic gathering of information (data) relevant to the 
research purpose or the specific objectives, questions, or hypothesis of a study”. 
Data was collected by the researcher and two research assistants (one health 
officer and one nurse).  Research assistants were trained regarding the purpose 
and objectives of the study, data collection instruments, data collection 
procedures and the ethical considerations during data collection. To accomplish 
the data collection process, each data collectors (the researcher and research 
assistants) were allocated to work on one facility each per day.  Before the start 
of the data collection activity, each selected ART clinics were communicated for 
their convenience day and time with in the period of data collection, September 
to October 2012.   
Respondents were provided with brief orientation on the purpose of the study 
and its significance then self-administered questionnaires were provided for 
those consented to participate in the study. The completed questionnaires were 
collected from each healthcare providers within 5-10 days from the date of 
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questionnaire was distributed and data quality check was done at the time of 
collection. 
3.3.3  Data analysis  
The purpose of data analysis is to organize, provide structure to, and elicit 
meaning from research data (Polit & Beck 2008).  Before any analysis is done, 
the data set must be carefully checked to identify any strange values and errors 
which might have occurred in the original source documents, during transcription 
or during data entry (Joubert & Katzenllenbogen 2007:127). 
The data collected for this study was coded and entered into the database 
designed with Epi-Info (windows version 3.5.4) which is a public domain 
statistical software developed by CDC, Atlanta, USA. The data set have been 
checked before the data analysis using the frequency tables and graphical 
displays that able the researcher to re-enter the missed values and fix data entry 
errors. The error cleaned data were then exported for analysis to a statistical 
package for social scientists (SPSS-version 21 IBM Corporation, USA). 
Descriptive statistics such as; frequency, percentage, mean and standard 
deviations were used primarily to summarize and describe the data. A chi-
square test was also used where appropriate to identify if relationships exists 
between categorical variables.  
Frequency distribution in terms of: 
 Socio-demographic characteristics 
 Levels of knowledge 
 Attitude towards IPT efficacy 
 Practice on IPT provision 
Cross-tabulations: 
Level of IPT practice behaviours with: 
 Socio-demographic variables; age, sex, marital-status and profession. 
 Level of clinical experience in HIV clinics. 
 Training condition on TB/HIV and IPT, in specific. 
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Association between: 
 Socio-demographic characteristics and practice 
 Knowledge and attitude 
 Knowledge and practice 
 Attitude and practice 
3.4  VALIDITY AND RELIABILITY OF THE STUDY 
According to Burns & Grove (2011:332-334), the validity of an instrument is a 
determination of how well the instrument reflects the abstract concept being 
examined, whereas, reliability is concerned with the consistency of the 
measurement method. 
3.4.1  Validity 
Validity refers to the extent to which a measurement instrument actually 
measures what it is meant to measure (Joubert & Katzenllenbogen 2007:117). It 
is the ability of a data collection instrument to measure what it was formulated to 
measure.  Content validity of the data collection tool for this study was based on 
recent guidelines for intensified TB case finding and IPT for PLHIV in resource-
limited settings, literature reviewed and experts' feedback. In addition, both the 
content and face validity was checked during the pilot study and by the experts 
in the related field; TB/HIV program managers.  
3.4.2  Reliability 
According to Joubert & Katzenllenbogen (2007:117), reliability or precision 
refers to the degree of similarity of the results obtained when the measurement 
is repeated on the same subject or same group.  
To address the reliability of this research instrument, the researcher referred 
guidelines such as; a guide to developing knowledge, attitude and practice 
surveys (WHO 2008), questionnaire annexes of guidelines for intensified TB 
case finding and IPT for people living with HIV in resource constrained settings 
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(WHO 2011d) as well as many different standard questionnaires of previous 
health research KAP assessments like; HIV/AIDS knowledge, attitudes, 
practices and perceptions of rural nurses in South Africa (Delobelle, Rawlinson, 
Ntuli, Malatsi, Decock & Depoorter 2009), Knowledge and attitudes of nurses 
regarding patients with acquired immunodeficiency syndrome (Eckstein 1987). 
KAP survey on professional nurses working at primary health care level in 
KwaZulu Natal (Mariani, Gcaba & Dalton 2003), Knowledge, attitude and 
practice of private practitioners regarding TB-DOTS in a rural district of Sindh, 
Pakistan (Ahmed, Fatmi, Ali, Ahmed & Ara 2009) and assessment of IPT 
outcome among HIV infected adults in public hospitals, the case of East Shewa 
zone of Oromia regional state in Ethiopia (Kumsa 2010). 
Basically, reliability was also assessed during the pilot test that the researcher 
was able to evaluate the instrument's precision or consistency from the 
response of healthcare providers. As a result, some appropriate corrective 
measures like; rephrasing and reordering of question items, adding more 
relevant questions and removing less relevant,  were taken to enhance the 
reliability of the instrument.   
3.5 ETHICAL CONSIDERATIONS 
The ethical principle of beneficence imposes a duty on researchers to minimize 
risks for respondents and to maximize possible benefits for both respondents 
and for the community as a whole (Polit & Beck 2008: 170). According to Burns 
& Grove (2011:107), three ethical principles are relevant to the conduct of 
researches involving human subjects: respect for persons, beneficence, and 
justice.  
3.5.1 Protecting the right of the participants 
All respondents in this research were given the right to self-determine to 
participate or to withdraw from the study at any time without the need for any 
explanation or justification. None of the questions included any kind of negative 
emotion or psychological trauma. No risk was associated with this research 
during the data collection process, and the results obtained from this study may 
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benefit for people living with HIV through improved provision of IPT by their 
healthcare providers.  
Justice means that respondents have an inalienable right to fair treatment and 
that the information that they impart for the purpose of research needs to be 
kept completely private (Polit & Beck 2008: 173). All information obtained from 
the respondents was treated confidentially and no names were mentioned in the 
questionnaire.   
3.5.2 Protecting the right of the institution 
Approval of ethical clearance has been secured from Research and Ethics 
Committee of the Department of Health Studies of the University of South Africa 
(UNISA) (annexure B) and Addis Ababa city administration health bureau 
(annexure D).  Permission and support letter, to conduct the study was then 
written by Addis Ababa city administration health bureau to the selected health 
facilities of study sites (annexures E&F).  
3.5.3 Scientific integrity of the research 
The researcher adhered to the principles of scientific integrity and honesty. All 
sources used in this study were acknowledged. 
3.5.4 Ethics pertinent to the research topic 
Ethical pertinence of this topic was evaluated and approved by the Research 
and Ethics Committee of the Department of Health Studies of UNISA and the 
city administration health bureau of Addis Ababa. Throughout the process of the 
study, the researcher had seriously supervised each step to address the 
expected ethical standards and kept the quality of research findings. The 
completed data was also checked for its completeness and consistency; any 
potential problems/shortcomings were addressed during the data collection. 
3.6 LIMITATIONS OF THE STUDY 
3.6.1 Study design 
A descriptive study design was used to describe the knowledge, attitude and 
practices of healthcare providers toward IPT provision for PLHIV. Descriptive 
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designs do not attempt to generalize the findings to populations outside the 
study participants. Therefore, findings of this study could not be generalized 
beyond the participants of the study in Addis Ababa and the rest of clinicians 
working in the other regions. 
3.6.2 Sampling method 
Cluster sampling was used to select the respondents of the study subjects 
assuming that the numbers of clinicians with in each cluster sites (health 
facilities) are equal. However, this might not be happened in the actual situation 
that might create sampling error (design effect) than the selection of study 
subjects from an equally and randomly un-clustered population. 
3.6.3 Data collection tool 
Another limitation of this study was that, it used a structured questionnaire to 
collect data from the study participants. This limited the responses that the 
respondents could choose from and did not have the capacity for in-depth 
answers.  
3.7 CONCLUSION 
This chapter described about the research design used in this study, the target 
population, the sample and sampling methods, the research instrument, data 
collection and data analysis methods. Reliability and validity issues as well as 
the ethical considerations have been also discussed.  
Next chapter discusses about data analysis, presentation and description of 
research findings.   
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CHAPTER 4 
ANALYSIS, PRESENTATION AND DISCUSION OF RESEARCH 
FINDINGS 
4.1  INTRODUCTION 
Chapter 3 presented about the research design and research methods. This 
chapter provides a detailed description of the results obtained from the data 
analysis of the survey. Results are described as simple percentages, means and 
standard deviations as appropriate depending on the nature of the variables. It 
starts with the demographic data followed by the responses for each section of 
the questionnaire. The level of knowledge, attitude and practice score were then 
presented and discussed. Lastly chi-square test was used to see whether there 
is any association between socio-demographic and practice score, knowledge 
and attitude, knowledge and practice and attitude and practice scores among 
the respondents. 
4.2  DATA MANAGEMENT AND ANALYSIS  
Data was collected from September 03, 2012 to October 12, 2012 using a 
structured and self-administered questionnaire, comprised of four sections; 
socio-demographic, knowledge, attitude and practice.  Epi-Info (v 3.5.4) was 
used for the data entry and exploratory analysis of data validation. Data was 
then exported to SPSS (v 21.0) for further analysis.  
Descriptive statistics was used to describe the characteristics of the sample from 
which the data were collected and chi-square test was applied to test whether 
differences between variables were significant at a statistical significance value 
of 0.05 and 95% level of confidence. Graphs and tables were used to depict the 
results of analysis findings. 
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4.3. RESEARCH RESULTS 
4.3.1. Sample characteristics 
Self-administered questionnaires were distributed for a total of 126 clinicians 
who were available in the study sites during the data collection period. Among 
the distributed questionnaires, data were collected from 117 healthcare 
providers from which 104 of them were completed whereas 13 were incomplete 
for most of the survey questions. According to Burns & Grove (2011:373), 
subjects must be excluded from the analysis when data considered essential to 
that analysis are missing.  As a result, 13 subjects were excluded from the 
analysis of the study. 
Therefore, the data analysis and discussion was made based on the feedback 
from a sample of n = 104 respondents.  
4.3.1.1 Gender 
 
Figure 4.1 Number and percentage of study partcipants by gender 
In this study, the majority of respondents (n = 71, 68.3%) were female whereas 
men encompassed only 31.7%.  
4.3.1.2 Age 
The mean age of the study subjects was 32 years with minimum age of 22 and 
maximum age of 52 years. Most of the respondents (n = 94, 89.5%) were 
Male,  
33 (31.7%) 
Female,  
71 (68.3%) 
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between 22 and 40 years and only one person (1%) was older than 50 years. 
(See Table 4.1 below) 
4.3.1.3 Level of profession 
The study was intended to target professionally qualified practitioners that are 
actively involved with the delivery of services for HIV/AIDS patients. In the 
present case, most of the respondents (n = 88, 84.6%) were nurses in 
profession out of which 59.6% (n = 62) had Bachelor degree whereas 25.0% (n 
= 26) were Diploma holders. The study also included Specialists (n = 4, 3.8%) 
and General Practitioners (GP: n = 2, 1.9%) as well as 8.7% of health Officers. 
 
Figure 4.2 Percentage of study partcipants by professional level 
4.3.1.4 Years of experience working in HIV/ART clinics 
As shown in Table 4.1 below, most of the study participants had an experience 
of working in HIV clinics for more than a year. Respondents with minimum 
experience of less than a year (greater than 6 months) were 14.4% (n=15) 
whereas with maximum experience of more than five years were 16.3% (n=17). 
4.3.1.5 Training on TB/HIV and IPT 
Most of the respondents, except 10.6% (n=11) were trained on TB/HIV 
collaborative activities in which IPT was included as one of the training 
Nurse 
Diploma 
25.0% 
Nurse 
Degree 
59.6% 
Health 
Officer 
8.7% 
GP 
1.9% 
Specialist 
3.8% 
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component and n=33, 31.7% of the respondents were also trained on IPT 
implementation program, in particular. 
Table 4.1: Distribution of the respondents by socio-demographic characteristics 
Variables Characteristics Number 
(n=104) 
Percentage (%) 
Gender Female  71 63 
Male 33 31.7 
    
Age group (years) 22 – 30 48 46.2 
31 – 40 45 43.3 
41 – 50 10 9.5 
51 and more   1 1.0 
 Mean= 32.55 
 
SD=6.36  Min=22   
Max=52 
Marital status Single 27 26.0 
Married 76 73.1 
Widowed   0 0.0 
Divorced   1 1.0 
    
Religion Christian 94 90.4 
Muslim 10 9.6 
Don't have any   0 0.0 
Other   0 0.0 
    
Profession level Nurse diploma 26 25.0 
Nurse B.Sc. 62 59.6 
Health officer   9 8.7 
GP   2 1.9 
Specialist   4 3.8 
    
Experience in HIV clinic ½ to 1 year 15 14.4 
1 to 3 years 48 46.2 
3 to 5 years 24 23.1 
More than 5 years 17 16.3 
   
Training on TB/HIV Yes 93 89.4 
No 11 10.6 
    
Training on IPT Yes 33 31.7 
No 71 68.3 
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4.3.2 Health facility composition 
To attain the number of targeted sample participants, a total of 22 ART clinics 
(annexure G) were visited, out of which 16 (72.7%) were from public and six 
(27.3%) were from private health facilities (Table 4.2). Among the sixteen public 
ART clinics, nine (56.2%) were found in health centers where as seven (43.8%) 
were in hospital settings. All private ART clinics were centered in hospital setting 
because ART service was approved only at the level of hospitals in case of a 
private facility.  
Table 4.2 Number of health facilities involved in the study  
 
        Facility Setting 
 Health Centre Hospital Total 
Facility 
Type 
Public 9 (56.2%) 7 (43.8%) 16 (72.7%) 
Private  6 (100%) 6(27.3%) 
 
Total 9 (40.9%) 13 (59.1%) 22 (100%) 
 
4.3.2.1 Study participants by the type of health facility  
Out of a total 104 respondents, 86 (82.7%) were from the public ART clinics 
while the remaining 18 (17.3%) clinicians were from private ART clinics (Figure 
4.3). 
 
Figure 4.3. Compostion of study partcipants by type of health facility 
Public,  
86 (82.7%) 
Private,  
18 (17.3%) 
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4.3.2.2 Study participants by settings of health facility  
As depicted in Figure 4.4 below, 62.5% of the study participants were from 
public and private hospitals where as the remaining were from the public health 
centers (primary care facilities).   
 
Figure 4.4 Number and percentage of study partcipants by their facility setting 
 
4.3.3  Knowledge of Healthcare providers regarding IPT 
Respondents answered a total of nine close-ended, multiple choice questions 
regarding IPT implementation and its efficacy. Each correct response was given 
one mark and 0 mark for wrong answers, with a total of nine marks. As shown in 
Table 4.3 below, the mean knowledge score for the respondents was 7.17 out of 
possible 9 points (SD = 1.16). Thirteen of the respondents were able to answer 
all the questions correctly while one respondent attained the minimum 
knowledge score of four. Most of the healthcare providers, who participated in 
the study (n = 74, 71.2%) had "high knowledge" and 27.9% (n = 29) of them had 
"moderate knowledge" while only one respondent had "low knowledge" 
regarding IPT efficacy and its implementation strategies. This finding, however, 
contrasts with a qualitative study conducted in South Africa that found out 
Hospital,  
65 (62.5%) 
Health center 
39 (37.5%) 
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healthcare providers' knowledge and experience were accounted as primary 
barriers for the wide implementation of IPT (Lester et al 2010:46). 
Table 4.3 Distribution of healthcare providers' knowledge level on IPT  
Level Number 
(n =104) 
Percentage 
(%) 
High (7-9 scores) 74 71.2 
Moderate (5-6 scores) 29 27.9 
Low (0-4 scores) 1 1.0 
Total 104 100.0 
Minimum =4         Maximum = 9 Mean =7.17 SD =1.16 
 
Responses for all questions of knowledge part of the questionnaire were 
summarized in Table 4.4 below. Almost all (>95%) of the respondents knew that 
INH (300 mg/day) is the best preventive drug to reduce the risk of TB infection 
among PLHIV. 92.4% of them also knew that "current cough, fever, weight loss 
and night sweet" are the four combinations of TB screening symptoms used to 
identify HIV-positive patients for IPT eligibility. The questions with the least 
number of correctly answered were 44.8% and 55.2%, regarding chest 
radiography requirement for IPT eligibility (knowledge item 3) and identifying 
patient's criteria  who is eligible to receive IPT (knowledge item 4), respectively. 
This indicates the work needed to further enhance the knowledge of the very 
practitioners as this might affect the start and follow-up of treatment. 
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Table 4.4: Number and percentage of healthcare providers who answered 
correctly on IPT knowledge questions (n=104). 
 Knowledge item Number 
(n=104) 
Percentage 
1. Do you think IPT reduces the risk of TB infection 
for HIV positive patients? 
102 97.1 
2. Which combinations of TB screening symptoms 
do you use to identify whether PLHIV are eligible 
for IPT or not? 
97 92.4 
3. Do you think chest radiography is a requirement 
for screening PLHIV for IPT eligibility?  
47 44.8 
4. Who is eligible to receive IPT? 58 55.2 
5. Do you think current pregnancy is a 
contraindication for starting IPT? 
79 75.2 
6. Can IPT be used as secondary prophylaxis for 
people with past history of TB? 
89 84.8 
7. Which one is the best TB preventive treatment 
drug? 
100 95.2 
8 Which one is the INH drug dose used for 
chemotherapy to prevent TB in adults living with 
HIV? 
104 99.0 
9 How do you assess whether your patients are 
adherent to IPT or not? 
69 65.7 
 
Similarly, figure 4.5 below presents graphically the number of healthcare 
providers by the correctness of responses for each knowledge items of the 
survey questions.  
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Figure 4.5: Number of respondents for each knowledge items of IPT. 
K1-K9 denotes the knowledge questions listed on Table 4.4. The data clearly 
shows where the knowledge gap is apparent in regards to the eligibility and 
chest radiography requirement issues to initiate IPT therapy. 
4.3.4. Attitude of healthcare providers towards IPT 
Attitude to a given a treatment modality by the very practitioners of healthcare 
providers is known to influence the course and outcome of a given therapeutic 
regimen. To evaluate this, respondents were asked to answer a total of nine 
Likert-scale questions with a total score of 45. Distribution of respondents' 
attitude towards IPT is shown in Table 4.5. As is indicated in the table, more 
than half (n = 72, 69.2%) of the healthcare providers are found to have a 
"positive attitude" and 26.9% (n = 28) of them had "neutral attitude" while only 
3.9% (n = 4) had "negative attitude" towards IPT provision. The mean attitude 
score for all respondents were 36.27 out of a possible 45 points (SD = 4.25). 
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The minimum and maximum range of attitude score was 25 and 43, 
respectively. 
Table 4.5 Distribution of healthcare providers' attitude level towards IPT 
Attitude level Number (n=104) Percentage 
Positive (36 - 45 scores) 72 69.2 
Neutral  (27 - 35 scores) 28 26.9 
Negative (09 - 26 scores)   4  3.9 
Total 104 100.0 
Mean = 36.27        SD  = 4.25 Min = 25 Max = 43 
 
The data  shown on Table 4.6 and Figure 4.6 shows that more than three-fourth 
of healthcare providers who participated in the study  were in a position of either 
“strongly agree” or “agree” with the entire attitude questions; implied they had a 
positive attitude towards IPT provision for PLHIV. A total 94.3% (with 73.1%: 
strongly agree and 21.2% agree) of the respondents agreed with a statement 
"IPT is effective in reducing TB incidence and mortality among PLHIV" and a 
total of 91.4% (58.7% strongly agree, 32.7% agree) of the respondents agreed 
with the national and international recommendations of IPT implementation. On 
the other hand, a total of 23% of the respondents were not agree with the 
statements that "IPT won't significantly increase the risk of developing INH-
resistance after excluding active TB " and  "the longer the duration of IPT (>6 
months), the longer the patient stays free from TB". However, the study trials 
from Botswana suggested that IPT benefit is increased with 36 months or longer 
duration than with a 6-month regimen (Samandari, Agizew, Nyirenda, Tedla, 
Sibanda, Shang, Mosimaneotsile, Motsamai, Bozeman, Davis, Talbot, Moeti, 
Moffat, Kilmarx, Castro & Wells 2011).  
  
51 
 
Table 4.6:The percentage of respondents and mean value of each attitude items 
 Attitude item Strongly 
agree 
Agree 
Unde
cided 
Disa
gree 
Strongly 
disagree 
Mean 
attitude 
1
. 
IPT is effective in reducing 
TB incidence and mortality 
among PLHIV. 
73.1 21.2 1.9 3.8 0 4.6 
2
. 
PLHIV who do not have 
current cough, fever, 
weight loss or night sweats 
are unlikely to have active 
TB and should be offered 
IPT. 
36.5 51.9 1.0 4.8 5.8 4.1 
3
. 
IPT should be given to all 
eligible PLHIV irrespective 
of their immune status. 
30.8 51.9 2.9 11.5 2.9 4.0 
4
. 
After excluding active TB, 
IPT won't significantly 
increase the risk of 
developing INH-resistance.   
17.3 59.6 4.8 15.4 2.9 3.7 
5
. 
Children < 1 year of age 
should be provided with 
IPT if they have a 
household contact history 
with a TB case. 
7.7 71.2 8.7 7.7 3.8 3.7 
6
. 
Pregnancy is not a 
contraindication for IPT 
provision. 
15.4 64.4 3.8 12.5 2.9 3.8 
7
. 
Past history of TB (>2 
years) is not a 
contraindication for IPT 
provision. 
27.9 61.5 0 7.7 2.9 4.0 
8 The longer the duration of 
IPT (>6 months), the 
longer the patient stays 
free from TB. 
51.0 26.0 5.8 11.5 5.8 4.0 
9 On overall, how do you 
agree that you are 
complying with the national 
and international IPT 
recommendations? 
58.7 32.7 1.9 0.0 4.8 4.4 
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Figure 4.6: Number of respondents for each Likert-scale attitude items of IPT  
 
4.3.5 Practice of healthcare providers towards IPT provision 
In the survey questionnaire, there were ten questions that asked the practice 
behaviour of healthcare providers towards IPT implementation according to the 
national guideline. Of the ten questions, six items were analysable in terms of 
practice frequency that each response was ranked 0 to 2 with a total of 12 
marks and the overall score was classified in to three levels of practice as, poor, 
fair and good.   
The mean practice score of IPT provision among healthcare providers, 
participated in this study, was 10.5 out of possible 12 points (SD = 1.21). As 
presented in Table 4.7 below, most of the respondents (n = 85, 81.7%) had 
"good practice" and 18.3% (n = 19) of them had "fair practice", while no one had 
"poor practice" on IPT implementation. The Range of respondents' practice 
scores was 7 - 12.  
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Table 4.7 Distribution of healthcare providers' practice level towards IPT 
provision 
Attitude level Number (n=104) Percentage 
Good (10 - 12 scores) 85 81.7 
Fair (7 - 9 scores) 19 18.3 
Poor (0 - 6 scores) 0 0.0 
Total 104 100.0 
Mean=10.5               SD  =1.21 Min=7 Max=12 
 
Data shown in Table 4.8 and Figure 4.7 summarizes response for the practice 
section of the questionnaire. All healthcare providers (85.6%: always, 14.4%: 
sometimes) were using the TB screening algorithm that basically relies on four 
clinical symptoms (current cough, fever, weight loss and night sweet) to identify 
patients for IPT eligibility. 61.5% of the respondents were always encouraging 
and providing advice for eligible patients to start IPT while 37.5% of them were 
advising their patients sometimes based on conveniences. More than half of the 
respondents (57.7%) were providing INH all the time once the patient was 
eligible while the rest of the respondents were providing sometimes depending 
on situations. Most of the respondents (90.4%) were advising patients who were 
put on IPT to adhere their treatment. This finding however contrasts with the 
previous study conducted in Addis Ababa that patients' non-adherence was 
observed due to the insufficient information about IPT by the healthcare 
providers (Mesele et al 2011). 
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Table 4.8: Number and percentage of respondents for each IPT practice items. 
 Practice item  Yes, 
always 
Yes, 
sometim
es 
No, at 
all 
Total 
1
. 
Do you use the TB screening 
tool (algorithm) to identify PLHIV 
eligible for IPT? 
N 89 15 0 104 
% 85.6 14.4 0.0 100.0 
2
. 
Do you encourage PLHIV to 
start IPT once they are eligible?   
N 64 39 1 104 
% 61.5 37.5 1.0 100.0 
3
. 
Do you provide INH for eligible 
HIV+ patients? 
N 60 44 0 104 
% 57.7 42.3 0.0 100.0 
5
. 
If you are providing IPT for your 
patients, how frequent do you 
supply the INH drugs?   * 
N 96 8 0 104 
% 92.3 7.7 0.0 100.0 
6
. 
Do you advice clients on IPT to 
adhere their treatment? 
N 94 10 0 104 
% 90.4 9.6 0.0 100.0 
7
. 
Do you monitor and manage 
clients with INH drug toxics 
N 70 28 6 104 
% 67.3 26.9 5.8 100.0 
 * INH supply on monthly and less days is ranked "2", on three months 
and per patients’ convenience is ranked "1" and ranked "0" for no 
supply. 
 
 
Figure 4.7: Number of respondents' response for each practice items of IPT  
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Among the ten questions of practice items in the questionnaire, two were asking 
about the number of PLHIV who started IPT by each respondent (P4) and if INH 
drug shortage was observed in their working site for the last one year (P8). 
Accordingly, Table 4.9 shows the summary of number of PLHIV who were put 
on IPT and only 55 of the respondents had answered to this practice item. 
Responses were grouped in to three levels as: less than 60% (low), 60 to 80% 
(moderate) and greater than 80% (high). Thirteen (23.6%) of the respondents 
had put their patients on IPT for more than 80% of PLHIV, while twenty-one 
(38%) of the respondents had put for less than 60% of their patients in the last 
one year.  On average, 60% of eligible HIV positive patients were put on IPT by 
the respondents in the last one year which is better than what was observed in 
the study by Wesen & Mitike (2012) in Addis Ababa and the routine report of 
Elmo (2011:22).  
Table 4.9: Percentage of PLHIV who were put on IPT in the last one year 
Percentage of  
PLHIV put on IPT 
Number of 
respondents 
Percentage of 
 respondents 
< 60% 21 38.2 
60 - 80% 21 38.2 
> 80% 13 23.6 
Total 55 100.0 
Mean= 60.4%             
 
Table 4.10 shows the summary of INH drug stock out status in the last one year 
of the assessment date. Most of the respondents (78%, n = 81) answered that 
INH shortage was not observed while 5.8% (n = 6) observed INH stock out for 
more than a month in their facility. This finding indicates that INH drug shortage 
possibly couldn't be a factor for the low implementation of IPT in Addis Ababa. 
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Table 4.10: INH drug stock out status in the last one year 
INH Stock out status Number of 
respondents 
Percentage of 
respondents 
No shortage 81 77.9 
Yes,  for less than a month 17 16.3 
Yes, for more than a month 6 5.8 
Total 104 100.0 
 
4.3.6 Comparison of practice score between grouping variables 
The chi-square (X2) test of independence determines whether two variables are 
independent or related; the test can be used with nominal or ordinal data (Burns 
& Grove 2011:401). In this study, associations between the study variables were 
assessed by X2 test and a probability two-sided value of p < 0.05 were used as 
the definition of significance to compare groups. 
4.3.6.1 Association between health facilities and IPT practice 
The practice behaviour of healthcare providers to provide IPT for PLHIV had no 
association with either of the facility types (public/private) or facility settings 
(hospital/health centre) where they work.  
4.3.6.1.1 Association between type of health facility and IPT practice 
The X2 test (p= 0.251) in Table 4.11 indicates that the association between type 
of health facility and level of IPT practice was not statistically significant.  This 
implied that significant evidence was not found from this study to say the level of 
IPT practice differs between the public and private type of health facilities.  
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Table 4.11: Association between type of health facility and IPT practice  
 
Level of Practice Chi-
square 
df 
P 
value 
Fair Good Total    
No. (%) No. (%) No. (%) 
 Public 14 (16.3) 72 
(83.7) 
86 (100)    
HF* type Private 5 (27.8) 13 
(72.2) 
18 (100) 1.318 1 .251 
 Total 19 (18.3) 85 
(81.7) 
104 
(100) 
   
*HF = health facility 
 
4.3.6.1.2 Association between health facility settings and IPT practice 
Association between facility setting and level of practice was insignificant 
(p=0.477)  that implied there is probably no difference in IPT practice of health 
care providers working in hospitals and health centre (primary care); or the 
difference in proportions of practice was observed only due to chance 
Table 4.12: Association between health facility settings and IPT practice 
 
Level of Practice Chi-
square 
df 
P 
value 
Fair Good Total    
No. (%) No. (%) No. (%) 
        
 Hospital 10 (15.4) 55 
(84.6) 
65 
(100) 
   
HF*setting Health 
center 
9 (23.1) 30 
(76.9) 
39 
(100) 
.507 1 .477 
 Total 19 (18.3) 85 
(81.7) 
104 
(100) 
   
*HF = health facility 
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4.3.6.2 Association between socio-demographic variables and IPT practice 
Socio-demographic variables of respondents; gender, age, marital status, 
religion, profession, experience hold in HIV clinics and whether he/she had been 
trained on IPT were tested to see the association they might have with the 
practice behaviour of the respondent towards IPT provision. The result is shown 
in Table 4.13 below and it indicated that no statistically significant difference was 
found between any of the groups.  
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Table 4.13: Association between respondents' socio demographic characteristics 
and IPT practice  
Socio-demographic  
characteristics 
Level of Practice Chi-
square 
df P value 
Fair Good Total    
No. (%) No. (%) No. (%) 
        
 Male 7 (21.2) 26 (78.8) 33 (100)    
Gender Female 12 (16.9) 59 (83.1) 71 (100) .280 1 .596 
 Total 19 (18.3) 85 (81.7) 104 (100)    
        
 20-30 8 (16.7) 40 (83.3) 48 (100)    
Age group 31-40 9 (19.6) 37 (80.4) 46 (100) 4.917 3 .178 
 41-50 1 (11.1) 8 (88.9) 9 (100)    
 >50 1 (100) 0 (0.0) 1 (100)    
 Total 19 (18.3) 85 (81.7) 104 (100)    
 Single 5 (18.5) 22 (81.5) 27 (100)    
Marital  Married 14 (18.4) 62 (81.6) 76(100) .226 2 .893 
status Divorced 0 (0.0) 1 (100) 1 (100)    
 Total 19 (18.3) 85 (81.7) 104 (100)    
        
 Christian 18 (19.1) 76 (80.9) 94 (100)    
Religion Muslim 1 (10) 9 (90) 10 (100) .507 1 .477 
 Total 19 (18.3) 85 (81.7) 104 (100)    
 Nurse Diploma 5 (18.5) 22 (81.5) 27 (100)    
Profession Nurse Degree 12 (19.4) 50 (80.6) 62 (100) .369 3 .947 
 Health Officer 1 (11.1) 8 (88.9) 9 (100)    
 Doctor/Specialist 1 (16.7) 5 (83.3) 6 (100)    
 Total 19 (18.3) 85 (81.7) 104 (100)    
        
 < 1 year 3 (20.0) 12 (80.0) 15 (100)    
 1 to 3 years 9 (18.8) 39 (81.3) 48 (100)    
Experience 3 to 5 years 5 (20.8) 19 (79.2) 24 (100) .625 3 .891 
 > 5 years 2 (11.8) 15 (88.2) 17 (100)    
 Total 19 (18.3) 85 (81.7) 104 (100)    
        
Training Yes 18 (19.4) 75 (80.6) 93 (100) .694 1 .405 
 No 1 (9.1) 10 (90.9) 11 (100)    
 Total 19 (18.3) 85 (81.7) 104 (100)    
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4.3.6.3 Association between healthcare providers’ knowledge, attitude and 
practice of IPT 
From the results of bivariate association test between knowledge, attitude and 
practice behaviour of healthcare providers towards IPT provision, significant 
difference (X2 =23.14, P=0.000) was found only between knowledge and attitude 
of respondents. The following tables (Table 4.11 to 4.13) provide details of these 
tests. 
4.3.6.3.1 Association between knowledge and attitude level of IPT 
Knowledge had highly statistically significant association with level of attitude 
towards IPT provision among the respondents (P=0.000). As level of knowledge 
increases (Table 4.14), proportion of respondents with positive attitude 
increases among respondents. 
Table 4.14: Association between knowledge and attitude level of IPT 
Level  
 
 Attitude 
X
2
 df 
P 
value 
Negative Neutral Positive Total    
No. (%)  No. (%) No. (%) 
 Low 0 (0.0) 0 (0.0) 1 (100.0) 1 (100)    
Knowl
edge 
Moderate 2 (6.9) 17 (58.6) 10 (34.5) 29 (100) 23.14 4 .000 
 High 2 (2.7) 11 (14.9) 61 (82.4) 74 (100)    
 Total 4 (3.8) 28 (26.9)  72 (69.2) 104 (100)    
 
4.3.6.3.2 Association between knowledge and practice level of IPT 
The statistic P=0.368 in Table 4.15 indicated that significant association was not 
found between knowledge and practice behaviour of respondents in the study. It 
implied that, the level of IPT practice was most likely the same among 
healthcare providers with moderate and high level of knowledge regarding IPT 
(except one, all respondents had knowledge level of moderate and above). 
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Table 4.15: Association between knowledge and practice level of IPT 
Level 
Practice 
X
2
 df P value 
Fair Good Total    
No. (%) No. (%) No. (%) 
 Low 0 (0.0) 1 (100.0) 1 (100)    
Knowledge Moderate 3 (10.3) 26 (89.7) 29 (100) 2.00 2 .368 
 High 16 (21.6) 58 (78.4) 74 (100)    
 Total 19 (18.3) 85 (81.7) 104 (100)    
        
 
4.3.6.3.3 Association between attitude and practice level of IPT 
The test result (X2 = 2.72, P = 0.257) indicated that the level of attitude had no 
significant association with the level of healthcare providers’ practice behaviour 
towards IPT provision.  
Table 4.16: Association between attitude and practice level of IPT 
Level  
Practice 
X
2
 df P value 
Fair Good Total    
No. (%) No. (%) No. (%) 
        
 Negative 0 (0.0) 4 (100.0) 4 (100)    
Attitude Neutral 3 (10.7) 25 (89.3) 28 (100) 2.72 2 .257 
 Positive 16 (22.2) 56 (77.8) 72 (100)    
 Total 19 (18.3) 85 (81.7) 104 (100)    
 
4.4  OVERVIEW OF RESEARCH FINDINGS 
The findings of this study show that the practice behaviour of healthcare 
providers towards IPT provision was not statistically significant on the level of 
knowledge and attitude they had regarding IPT efficacy. However, the attitude of 
healthcare providers towards IPT provision was significantly associated with the 
level of knowledge on IPT. In addition, the socio and demographic 
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characteristics of healthcare providers didn’t depict significant association with 
the level of practice behaviour on IPT implementation.  
 
4.5  CONCLUSION 
This chapter has provided a detailed description of the study findings. The 
results from the survey questionnaire were presented and discussed according 
to the individual items and overall scores of the knowledge, attitude and practice 
questions. The overall score of IPT practice behaviour was then tested for any 
statistically significant relationship between the major demographic 
characteristics as well as the overall scores of knowledge and attitude of the 
study participants. 
In the next chapter, significance of the study findings, limitations of the study, 
implications for practice and recommendations for further researches will be 
presented.  
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CHAPTER 5 
CONCLUSIONS AND RECOMMENDATIONS 
5.1  INTRODUCTION 
Effective and efficient delivery of a professional societal service demands the 
rigorous scientific understanding and practical implementation by the 
practitioners of the profession. That is especially so in the area of health service 
delivery. With this in mind, this study was initiated to assess the level of 
healthcare providers’ knowledge, attitude and practice towards IPT provision in 
Addis Ababa, Ethiopia. In this chapter, a brief description of the major findings, 
significance of the study and its limitations as well as researcher’s 
recommendations for practice and further researches will be discussed. 
 
5.2.  RESEARCH DESIGN AND METHOD 
A quantitative, descriptive cross-sectional research design was employed in this 
study in which numerical data were collected at one point in time to describe the 
characteristics of the study variables. The data was obtained from a facility-
based study conducted at twenty-two antiretroviral therapy treatment centres. 
The sources for the study were healthcare providers working at the study sites 
who had at least six months experience in providing treatment for people living 
with HIV.  
A total of 140 healthcare providers from the randomly selected public and 
private health facilities were communicated to participate in this study and 
provided the self-administered structured questionnaire. Out of which, 104 
(74%) health care providers have returned the completed form of questionnaire 
that the entire analysis was based on these numbers of study participants. 
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5.3  SUMMARY AND INTERPRETATION OF RESEARCH FINDINGS  
The findings from this study are discussed according to the objectives of the 
study as follows. The study objectives were: 
 Assess the knowledge, attitude and practice level of healthcare providers 
towards IPT provision for people living with HIV. 
 Determine if significant relationships exist between healthcare providers' 
IPT practice and their working settings (private vs. public). 
 Determine if significant relationships exist between healthcare providers' 
IPT practice and the level of their knowledge and attitude on IPT. 
5.3.1 Assess healthcare providers’ knowledge, attitude and practice 
towards IPT provision for PLHIV. 
5.3.1.1 Level of healthcare providers’ knowledge regarding IPT  
The result on the level of healthcare providers’ knowledge about IPT shows that, 
out of a total 104 healthcare providers, 74 (71%) had high knowledge and 29 
(28%) had moderate knowledge while only one respondent (1%) had low 
knowledge. The mean score was found to be 7.17 out of the possible 9 points 
with a standard deviation of 1.16. Clearly this shows that the mean knowledge 
level of respondents who participated in this study were high. This might be 
because most of the respondents had been trained on TB/HIV collaborative 
activities, including IPT (89.4%) and had an experience of working in HIV clinics 
for more than a year (85.6%).  
More than 90% of the respondents had correctly answered for the questions on 
the combinations of TB screening tools to identify whether PLHIV are eligible for 
IPT, the type of TB preventive drug and its dosage. This implies that healthcare 
providers who participated in this study had good knowledge of screening 
people living with HIV to identify them for IPT eligibility as well as the type of 
65 
 
drug and dosages used to prevent HIV patients (without active TB) from TB 
infection. 
On the other hand, more than half of the respondents (55.2%) incorrectly 
answered the question on the necessity of chest radiography for screening 
PLHIV for IPT eligibility. According to the revised WHO IPT guideline (2011b:8), 
chest radiography is no longer a mandatory investigation before starting IPT. I.e. 
chest radiography can be done if available, but is not required to classify 
patients into TB and non-TB groups. Nearly half of the respondents (45.8%) 
were also missed to answer correctly on the question about who can be eligible 
to receive IPT. Though WHO (2011b:11) recommends that IPT should be 
provided for all community groups of HIV positive patients who don’t have active 
TB and all children and infants less than one year of age in contact with smear 
positive TB case, respondents of this study were more in favour of only the 
community group of HIV positive patients without active TB. These results 
therefore indicate that program managers need to devise interventions that will 
target healthcare providers’ knowledge regarding the option of chest-
radiography for TB screening to put patients on IPT and on the general criteria 
of IPT eligibility for paediatric groups. 
Another important area that 34.3% of respondents lacked the knowledge was 
the way how healthcare providers assess their patients’ adherence to IPT (refer 
to Table 4.4). Patient adherence to INH therapy is a key factor in determining 
the effectiveness of IPT intervention. Therefore, it is necessary that healthcare 
providers need to know how to assess patients’ adherence level and provide 
them adequate information on the pros and cons of poor IPT adherence.  
5.3.1.2 Level of healthcare providers’ attitude towards IPT provision 
On the level of healthcare providers’ attitude towards IPT provision, the finding 
of this study revealed that 69% of healthcare providers who participated in this 
study had positive attitude whereas 27% of them were neutral; in a position of 
neither supporting nor opposing the provision of IPT for PLHIV.  The mean 
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survey score of respondents’ attitude was found to 36.27 from a possible 45 
points with a standard deviation of 4.25. Evidently, this shows that those 
healthcare providers who participated in this study had on average a positive 
attitude towards IPT provision and this could be because of most respondents 
had high level of knowledge on IPT efficacy. This finding however contrasts with 
a study of Getahun et al. (2010) on global IPT implementation barriers and 
solutions that found out as the lack of experience, knowledge and clarity on the 
benefits of IPT by health care workers were among barriers of IPT 
implementation globally.  
5.3.1.3 Level of healthcare providers’ practice towards IPT provision 
The study to assess the level of healthcare providers’ practice towards IPT 
provision shows that 81.7% of the respondents had good practice and 18.3% of 
them had fair practice on IPT. The mean score of IPT practice was 10.5 out of 
possible 12 points with a standard deviation of 1.21. This indicates that 
healthcare providers who participated in this study had on average good 
practice of IPT implementation that includes activities like; the screening of 
people living with HIV for TB, encouraging eligible patients to start IPT,  
providing  INH for eligible persons and monitoring the side effects on a follow up 
time.  
5.3.2 Association between healthcare providers’ working settings and 
level of IPT practice 
The results on the impact of healthcare providers’ working settings and level of 
IPT practice study demonstrated that there were no significant differences in the 
practice behaviour of healthcare providers on the basis of their working settings. 
Respondents who worked either in public or private health facilities had on 
average positive attitude and good practice of IPT and the same was true in 
health centres and hospital settings. Therefore, as per this finding, there is no 
need to devise interventions that will target healthcare providers in different 
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working settings; as hospital vs. health centre and public vs. private types of 
health facilities. 
5.3.3 Association between healthcare providers’ knowledge, attitude and 
level of IPT practice 
Lastly, the association between healthcare providers’ knowledge, attitude and 
level of IPT practice was examined and the data suggest that there exist a 
significant relationship between knowledge and attitude (P=0.000). It means 
that, increasing the knowledge level of healthcare providers will impress their 
attitude behaviour. On the other hand, the result demonstrated that knowledge 
and attitude had no significant association with practice score of IPT. This might 
be because there were no significant differences of knowledge and attitudes 
within the groups of participants. 
 
5.4  CONCLUSION 
Overall, the results of this study revealed that healthcare providers who 
participated in this study had on average a high level of knowledge, positive 
attitude and good practice towards IPT provision for people living with HIV.  This 
implies, therefore, the low level of IPT utilization in Ethiopia and in particular, 
Addis Ababa, could not be due to the clinician’s resistance to provide IPT for 
people living with HIV. 
 
5.5 RECOMMENDATIONS 
Based on the findings, some recommendations are suggested for practice to 
effectively implement IPT in healthcare settings and increase its uptake among 
people living with HIV. In addition, the researcher highlights areas of gaps 
recommended for further research in the perspective of healthcare providers’ 
knowledge, attitude and practice towards IPT provision. 
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5.5.1  Practice 
The Health Bureau and the Ministry of Health together with the existing health 
partner organizations need to: 
 
 Conduct training to improve clinicians’ knowledge on the updated 
recommendations of IPT and the identified knowledge gaps like; chest 
radiography for IPT start up, IPT for children, IPT for pregnant women 
and patient assessment for IPT adherence.   
 Organize refresher courses or awareness promotion workshops to 
promote the attitude of healthcare providers towards the belief that INH 
increases the risk of drug-resistant, IPT contra-indication with pregnancy, 
IPT initiation irrespective of the immune and/or ART status, and other 
controversial issues of IPT. 
 Distribute the updated national guideline for clinical and programmatic 
management of TBL and TB/HIV (integrated national guideline including 
IPT) as much as possible to all health facilities, especially ART clinics for 
the use by healthcare providers as a reference. 
 Monitor and follow up the actual implementation of IPT through providing 
supportive supervision and in-placing effective information management 
system so that IPT implementation activities are well kept and reported in 
a standard system to the regional health bureau. 
5.5.2  Further research 
Finally, in order to answer fully for the problem why Ethiopia reports low level of 
IPT implementation every year, further researches need to be conducted on the 
following topics:  
 Conduct similar studies in the other regions of Ethiopia. Due to time and 
resource limitation, the study has been conducted only in Addis Ababa 
and hence it might not be a representative of the country as a whole. In 
future, more studies should be conducted in other regions to find out the 
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pattern of healthcare providers’ knowledge, attitude and practice towards 
IPT provision for people living with HIV. 
 Review the medical records of HIV positive patients and identify the rate 
of IPT provision among eligible persons so that practice level of 
healthcare providers is measured from their action and,  
 Assess the information management system of TB/HIV collaborative 
activities along with the reliability of data recording and reporting system 
from health facility up to the national level.  
 
 
5.6  CONTRIBUTIONS OF THE STUDY 
This study contributes towards healthcare authorities and partner organizations, 
who implement TB/HIV collaborative activities, as an input during intervention 
plans and operational research to widely scale up IPT implementation in Addis 
Ababa and in the country, as appropriate. In addition, findings of this study 
contribute as reference to individual researchers on IPT assessment in the 
perspective of healthcare providers which had been rarely conducted before in 
Addis Ababa. 
 
5.7 LIMITATIONS OF THE STUDY 
Because this study was conducted only in selected health facilities of Addis 
Ababa, it may not be applicable to generalize the findings to the whole country. 
Another limitation is, even though the data was collected using a structured 
questionnaire, it was self-reported and one cannot discount the existence of a 
personal desirability bias that respondents might not have reported their actual 
perception and practice behaviour.   
5.8. CONCLUDING REMARK 
The present study assessed healthcare providers’ level of knowledge, attitude 
and practice towards IPT provision for PLHIV in Addis Ababa. The findings and 
recommendations should serve to further improve knowledge and attitude of 
70 
 
healthcare providers that ultimately increases the wide implementation of IPT 
not only in Addis Ababa, but also in the entire country. The researcher also 
believes this study will contribute significantly to open a door for further 
researches on clinicians’ perception and practice towards IPT provision for 
PLHIV in other regions of the country.  
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ANNEXURES 
 
Annexure A: Questionnaire 
 
Data Collection Form 
Dear respondent, you are invited to participate in this research voluntarily and 
kindly requested to respond to the following questions that asks about your 
socio-demography, knowledge, attitude and practice towards IPT provision for 
people living with HIV. The result of this study will be important to plan activities 
for the wide implementation of IPT in Addis Ababa, and in the country in general.   
Understanding that your honest and genuine response will have significant contribution 
to the success of this study, please take your time to respond to all questions. No name 
is going to be on the questionnaire and the information you give will be kept strictly 
confidential. 
Thanks in advance! 
 
 
Instruction for respondents: for each of the following sections, please circle 
one of your best choice or answer as appropriate to the specific item of the 
question. 
 
 
 
(General items to be filled by the researcher or research assistant) 
Respondent number: ____|_____|______  Name of health facility: 
____________________  
Facility setting: 1.   Hospital 2.   Health centre   3.  Higher clinic 
Facility type:   1.   Public 2.    Private 
  
SECTION 1:  SOCIO-DEMOGRAPHIC DATA 
1.1 Gender 1.   Male 2.  Female  
1.2  Age (in years): _____________________ 
1.3  Marital status  1. Single 2.  Married 3. Widowed 4. Divorced       
1.4  Religion   1. Christian 2. Muslim 3. Don’t have any 4. Other, 
1.5  Professional level 1. Nurse-Diploma    2. Nurse-Degree  
                 3.  Health Officer        4.   General practitioner 
                   5.  Specialist         6.   Other: _________________ 
1.6     How long have you worked in HIV clinic?           1.   Less than 1 year 
              2.  1 to 3 years              3.  3 to 5 years        4.   More than 5 years                            
 
1.7 Have you ever been trained on TB and HIV collaborative activities? 
      1. Yes        2. No 
1.8 Have you ever been trained specifically, on IPT?  
               1. Yes       2. No 
SECTION 2:  KNOWLEDGE ABOUT IPT 
2.1 In your opinion, do you think 
that IPT reduces the risk of TB 
infection for HIV positive 
patients?  
1. Yes 
2. No 
 
 
 
2.2 Which combinations of TB 
screening symptoms do you 
use to identify whether PLHIV 
are eligible for IPT or not? 
1. Current cough, rash, weight loss, fever 
2. Fever, current cough, night sweet, rash 
3. Current cough, fever, weight loss, night 
sweet 
4. Weight loss, nausea, fever, rash 
 
2.3 Do you think chest radiography 
is a requirement for screening 
PLHIV for IPT eligibility?  
1. Yes 
2. No 
 
2.4 In your opinion, who is eligible 
to receive IPT? 
1. All infants of mother with pulmonary TB 
2. All children <5 yrs in contact with smear 
positive TB patient 
3. All HIV positive patients who don’t have 
active TB 
4. All above cases 
5. Only 2 & 3  
 
 2.5 Do you think current pregnancy 
is a contraindication for starting 
IPT? 
 
1. Yes 
2. No 
2.6 Can IPT be used as secondary 
prophylaxis for people with past 
history of TB? 
 
1. Yes 
2. No 
 
2.7 Which one is the best TB 
preventive treatment drug? 
1. Isoniazid (INH) 
2. Rifampicin (RIF) 
3. Pyrazinamide (PZA) 
4. None 
2.8 Which one is the INH drug dose 
used for chemotherapy to 
prevent TB in adults living with 
HIV? 
 
1. 100 mg/day 
2. 200 mg/day 
3. 300 mg/day 
4. 150 mg/day 
5. None of the above 
 
2.9 How do you assess whether 
your patients are adherent to 
IPT or not? 
 
1. Patient self-report 
2. Detailed interview 
3. Pill counts 
4. Pharmacy refill data 
5. All above 
6.  None of the above 
2.10 In your opinion, mention the 
major barriers for successful 
implementation of IPT in your 
area?   
1. ________________________________ 
2. ________________________________ 
3. ________________________________ 
4. ________________________________ 
5. ________________________________ 
6. ________________________________ 
 
SECTION 3: ATTITUDE TOWARDS IPT EFFICIANCY AND PROVISION 
Please select only one response that best suits among the likert-scale measurements 
of your attitude.  
3.1 IPT is effective in reducing TB 
incidence and mortality 
among PLHIV.  
1. Strongly agree     
2. Agree   
3. Undecided 
4. Disagree    
5. Strongly disagree        
 
3.2 PLHIV who do not have 1. Strongly agree     
 current cough, fever, weight 
loss or night sweats are 
unlikely to have active TB and 
should be offered IPT. 
 
2. Agree   
3. Undecided 
4. Disagree    
5. Strongly disagree     
 
3.3 IPT should be given to all 
eligible PLHIV irrespective of 
their immune status. 
1. Strongly agree     
2. Agree   
3. Undecided 
4. Disagree    
5. Strongly disagree 
 
3.4 After excluding active TB, IPT 
won't significantly increase the 
risk of developing INH-
resistance.   
 
1. Strongly agree     
2. Agree   
3. Undecided 
4. Disagree    
5. Strongly disagree   
 
3.5 Children < 1 year of age 
should be provided with IPT if 
they have a household 
contact history with a TB 
case.  
 
1. Strongly agree     
2. Agree   
3. Undecided 
4. Disagree    
5. Strongly disagree   
 
3.6 Pregnancy is not a 
contraindication for IPT 
provision  
1. Strongly agree     
2. Agree   
3. Undecided 
4. Disagree    
5. Strongly disagree        
3.7 Past history of TB (>2 years) 
is not a contraindication for 
IPT provision 
1. Strongly agree     
2. Agree   
3. Undecided 
4. Disagree    
5. Strongly disagree     
 
3.8 The longer the duration of IPT 
(>6 months), the longer the 
patient stays free from TB. 
1. Strongly agree     
2. Agree   
3. Undecided 
4. Disagree    
5. Strongly disagree    
 
3.9 On overall, do you agree that 
you are complying with the 
national and international IPT 
recommendations? 
1. Strongly agree     
2. Agree   
3. Undecided 
4. Disagree    
5. Strongly disagree    
  
3.10 If not agree for Q3.9, mention 
your major beliefs preventing 
you from complying the 
recommendations? 
1. ________________________________ 
2. _________________________________ 
3. _________________________________ 
4. _________________________________ 
5. _________________________________ 
 
SECTION 4:   PRACTICE ON  IPT PROVISION 
4.1 Do you use the TB screening 
tool (algorithm) to identify 
PLHIV eligible for IPT? 
1. Yes, always 
2. Yes, sometimes 
3. No 
 
 
4.2 Do you encourage PLHIV to 
start IPT once they are 
eligible?   
1. Yes, always 
2. Yes, sometimes 
3. No 
4.3 Do you provide INH for 
eligible HIV+ patients? 
1. Yes,  always 
2. Yes, sometimes 
3. No  
4.4 If your answer for Q4.3 is 
‘Yes’, how many of the ten 
newly enrolled HIV+ patients 
started IPT in the last one 
year? 
 
_______________of ten patients started IPT. 
4.5 If you are providing IPT for 
your patients, how frequent 
do you supply the INH drugs? 
 
1. Daily 
2. Weekly 
3. Monthly 
4. Every 3 months 
5. Per patients convenience 
4.6 Do you advice clients on IPT 
to adhere to their treatment? 
1. Yes,  always 
2. Yes, sometimes 
3. No 
4.7 Do you monitor and manage 
clients with INH drug toxics? 
1. Yes, always 
2. Yes, sometimes 
3. No 
 
4.8 If your answer for Q4.3 is 
‘No’, what hinders you from 
putting the patient on IPT?  
 
1. Fear of INH-resistance  
2. Fear of developing side effects 
3. Difficult to exclude active TB  
4. Not sure on the benefit of IPT 
5. No adequate knowledge on  IPT 
  
 
Thank you for your patience and genuine response! 
  
(Multiple answer is possible) 6. Patients refuse to take IPT 
7. Patients’ poor adherence 
8. TST is unavailable 
9. Chest x-ray is unavailable 
10. INH is unavailable  
11. Other, specify 
_______________________ 
 
4.9 Did you experience INH stock 
out in the last one year? 
1. Yes,  for less than a month  
2. Yes, for more than a month  
3. No shortage 
4. N/A 
 
4.10 Please mention the major 
interventions required for the 
successful implementation of 
IPT in your area.  
 
1. _________________________________ 
2. _________________________________ 
3. _________________________________ 
4. _________________________________ 
5. _________________________________ 
 
 
 Annexure B: UNISA ethical clearance certificate 
 
  
 Annexure C: Addis Ababa City Administration Health Bureau application  
  to conduct research 
 
To:   Addis Ababa City Administration Health Bureau 
P.o. Box 30738 
Addis Ababa 
 
August 24, 2012 
Subject: request for permission to carry out a research for academic 
purposes 
Dear Sir/Madam 
I am a student at the University of South Africa (UNISA) in Master of Public Health 
(MPH). As mentioned above, I want to carry out a research for the partial fulfilment my 
study on the topic “knowledge, attitude and practice of healthcare providers towards 
isoniazid preventive therapy (IPT) provision for people living with HIIV in Addis Ababa in 
selected public and private ART clinics as listed on the attachment.  
The objectives of my study are: 
 To assess and describe the knowledge, attitude and practice of healthcare 
providers towards IPT provision for people living with HIV. 
 To determine if significant relationships exist between healthcare providers' IPT 
provision and their level of knowledge and attitude. 
 To determine if significant relationships exist between healthcare providers' IPT 
provision and their working setting (private or public institution). 
 
When the study completed, I will submit the result for subsequent use of the findings for 
it may help to improve the wide use of IPT in Addis Ababa and the country, at large. 
Therefore, I kindly request your esteemed organization to allow me to conduct this 
research as part of my academic requirements. Annexed are the ethical approval letter 
from UNISA, research instrument, respondents' consent form and the proposal for 
further review.  
Sincerely, 
AzmeraMollaTikuye 
 Annexure D: Addis Ababa City Administration Health Bureau ethical  
  review committee research approval  
  
 Annexure E:  Addis Ababa City Administration Health Bureau letter to the 
study public-health facilities to conduct approved research 
 
  
 Annexure F:  Addis Ababa City Administration Health Bureau letter to the 
study private-health facilities to conduct approved research 
 
 Annexure G: List of study health facilities  
No. Facility Name Facility setting Facility type 
1 Arada health center Health centre Public 
2 Bole health center “ “ 
3 Kasanchis health center “ “ 
4 Kolfae health center “ “ 
5 Lideta health center “ “ 
6 Selam health center “ “ 
7 Wereda 09 health center “ “ 
8 Wereda 19 (Nifassilk No.1) health center “ “ 
9 Yeka health center “ “ 
10 Ghandi hospital Hospital “ 
11 Minilik hospital “ “ 
12 Rasesta hospital “ “ 
13 St Peter hospital “ “ 
14 TikurAnbessa hospital “ “ 
15 Yekatit 12 hospital “ “ 
16 Zewditu hospital “ “ 
17 Bethezata hospital “ Private 
18 Hayat hospital “ “ 
19 MCM hospital “ “ 
20 National hospital “ “ 
21 St .Gabriel hospital “ “ 
22 St .Yared general hospital “ “ 
 
